EP3992195B1 - Spiro (3,3'-isopropyl pyrrolidine oxindole) liver x receptor regulator, preparation method therefor, and use thereof - Google Patents
Spiro (3,3'-isopropyl pyrrolidine oxindole) liver x receptor regulator, preparation method therefor, and use thereof Download PDFInfo
- Publication number
- EP3992195B1 EP3992195B1 EP20841629.7A EP20841629A EP3992195B1 EP 3992195 B1 EP3992195 B1 EP 3992195B1 EP 20841629 A EP20841629 A EP 20841629A EP 3992195 B1 EP3992195 B1 EP 3992195B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- cooh
- compound
- independently
- halogenated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 title claims description 20
- 102000004311 liver X receptors Human genes 0.000 title description 46
- 108090000865 liver X receptors Proteins 0.000 title description 46
- PCKPVGOLPKLUHR-UHFFFAOYSA-N OH-Indolxyl Natural products C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 title description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title description 7
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title description 6
- 238000002360 preparation method Methods 0.000 title description 4
- 125000003003 spiro group Chemical group 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 151
- -1 hydrate Substances 0.000 claims description 109
- 229910052801 chlorine Inorganic materials 0.000 claims description 52
- 229910052731 fluorine Inorganic materials 0.000 claims description 52
- 229910052794 bromium Inorganic materials 0.000 claims description 51
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 229910052805 deuterium Inorganic materials 0.000 claims description 50
- 229910052740 iodine Inorganic materials 0.000 claims description 50
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 48
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000003545 alkoxy group Chemical group 0.000 claims description 25
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000004429 atom Chemical group 0.000 claims description 20
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 18
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 15
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 claims description 15
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 15
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 14
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 13
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 13
- 208000004930 Fatty Liver Diseases 0.000 claims description 13
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 13
- 208000010706 fatty liver disease Diseases 0.000 claims description 13
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 13
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 12
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 12
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 12
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 12
- 208000008589 Obesity Diseases 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 12
- 235000020824 obesity Nutrition 0.000 claims description 12
- 239000012453 solvate Substances 0.000 claims description 12
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 8
- 201000008937 atopic dermatitis Diseases 0.000 claims description 8
- 230000037149 energy metabolism Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 7
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 7
- 208000001132 Osteoporosis Diseases 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 7
- 208000005017 glioblastoma Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 5
- 230000008685 targeting Effects 0.000 claims description 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 229940125753 fibrate Drugs 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- QDGIAPPCJRFVEK-UHFFFAOYSA-N (1-methylpiperidin-4-yl) 2,2-bis(4-chlorophenoxy)acetate Chemical compound C1CN(C)CCC1OC(=O)C(OC=1C=CC(Cl)=CC=1)OC1=CC=C(Cl)C=C1 QDGIAPPCJRFVEK-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims description 2
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical group O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 2
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 2
- 229960005370 atorvastatin Drugs 0.000 claims description 2
- 229960000516 bezafibrate Drugs 0.000 claims description 2
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001214 clofibrate Drugs 0.000 claims description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical group CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 2
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 claims description 2
- 229960003345 empagliflozin Drugs 0.000 claims description 2
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims description 2
- 229960004783 fotemustine Drugs 0.000 claims description 2
- 229960003627 gemfibrozil Drugs 0.000 claims description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 2
- 229960004346 glimepiride Drugs 0.000 claims description 2
- 229950009619 lifibrate Drugs 0.000 claims description 2
- 229960004844 lovastatin Drugs 0.000 claims description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 229960004270 nabumetone Drugs 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 229960002354 repaglinide Drugs 0.000 claims description 2
- 229960002855 simvastatin Drugs 0.000 claims description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
- 229960004964 temozolomide Drugs 0.000 claims description 2
- 229960001032 trihexyphenidyl Drugs 0.000 claims description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 38
- 230000000694 effects Effects 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 239000000460 chlorine Substances 0.000 description 28
- 239000000047 product Substances 0.000 description 24
- 239000007787 solid Substances 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 125000003118 aryl group Chemical group 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 229940002612 prodrug Drugs 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 7
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 7
- 101710159293 Acyl-CoA desaturase 1 Proteins 0.000 description 7
- 108010018763 Biotin carboxylase Proteins 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 7
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 6
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001204 N-oxides Chemical class 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000003419 tautomerization reaction Methods 0.000 description 5
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960002297 fenofibrate Drugs 0.000 description 4
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229940125425 inverse agonist Drugs 0.000 description 4
- 150000002611 lead compounds Chemical class 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000008078 Sterol Regulatory Element Binding Protein 1 Human genes 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 2
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JMLWXCJXOYDXRN-UHFFFAOYSA-N 1-chloro-3-iodobenzene Chemical compound ClC1=CC=CC(I)=C1 JMLWXCJXOYDXRN-UHFFFAOYSA-N 0.000 description 2
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 2
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 2
- 125000004922 2-methyl-3-pentyl group Chemical group CC(C)C(CC)* 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 2
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 2
- 125000004921 3-methyl-3-pentyl group Chemical group CC(CC)(CC)* 0.000 description 2
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229940122761 Liver X receptor agonist Drugs 0.000 description 2
- 229940111985 Liver X receptor inverse agonist Drugs 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108010052090 Renilla Luciferases Proteins 0.000 description 2
- FYQFEJFTCLKXTQ-UHFFFAOYSA-N SR9243 Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)N(CC=1C=CC(=CC=1)C=1C=C(C=CC=1)S(C)(=O)=O)CCC1=CC=CC(Br)=C1 FYQFEJFTCLKXTQ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000011914 asymmetric synthesis Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- HDZWHJYZJWLTAG-UHFFFAOYSA-N ethyl 5-[[[4-(3-methylsulfonylphenyl)phenyl]methyl-(2,4,6-trimethylphenyl)sulfonylamino]methyl]furan-2-carboxylate Chemical compound O1C(C(=O)OCC)=CC=C1CN(S(=O)(=O)C=1C(=CC(C)=CC=1C)C)CC1=CC=C(C=2C=C(C=CC=2)S(C)(=O)=O)C=C1 HDZWHJYZJWLTAG-UHFFFAOYSA-N 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000766 liver X receptor agonist Substances 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 210000000229 preadipocyte Anatomy 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- ASQOQJYHIYYTEJ-GBESFXJTSA-N (1r,7s,9as)-7-decyl-2,3,4,6,7,8,9,9a-octahydro-1h-quinolizin-1-ol Chemical compound O[C@@H]1CCCN2C[C@@H](CCCCCCCCCC)CC[C@H]21 ASQOQJYHIYYTEJ-GBESFXJTSA-N 0.000 description 1
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- XGSWAPNRKGOSKD-UHFFFAOYSA-N 2-[2-(2-phenylethyl)phenyl]isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1CCC1=CC=CC=C1 XGSWAPNRKGOSKD-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical class C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 238000006929 Pictet-Spengler synthesis reaction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000002171 adipose macrophage Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-M alpha-D-galacturonate Chemical compound O[C@H]1O[C@H](C([O-])=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-M 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940052651 anticholinergic tertiary amines Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229950007655 esilate Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
- 150000002390 heteroarenes Chemical class 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000005623 oxindoles Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000003030 reporter gene method Methods 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present disclosure relates to the field of biomedicines. Specifically, the present disclosure relates to a 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver X receptor regulator, a preparation method therefor, and uses thereof.
- Liver X receptor is a ligand-dependent transcription factor that usually forms a heterodimer in a form of LXR/RXR together with retinol X receptor (RXR).
- LXR can be bonded to an LXR response element (LXRE) on the target gene to regulate a transcription process of the target gene.
- LXR includes two subtypes, i.e., LXR ⁇ and LXR ⁇ .
- LXR ⁇ is distributed in liver, small intestine, adipose tissue, and macrophages with immune functions, while LXR ⁇ is widely distributed throughout the body.
- LXR is a nuclear receptor activated by oxysterols, and plays an important role in fat, cholesterol, and sugar metabolisms, and inflammation. It has broad development prospects to develop new drugs targeting at LXR.
- the synthetic LXR agonists include GW3965 and TO901317, etc.
- the LXR agonists can be developed and used as lead compounds for the treatment of atherosclerosis, cancer, Alzheimer's disease, atopic dermatitis, and other diseases.
- LXR antagonists or inverse agonists mainly including SR9243, SR9238, PP2P, fenofibrate, morin, and luteolin, etc.
- LXR antagonists or inverse agonists have strong anti-fatty liver activity.
- the mechanism of LXR antagonists or inverse agonists for lipid-lowering is to down-regulate sterol regulatory element-binding protein (SREBP-1c) of LXR target gene, acetyl-coA carboxylase (ACC), lipese (FAS), and stearoyl-CoA desaturase-1 (SCD-1), so as to reduce triglyceride synthesis.
- SREBP-1c sterol regulatory element-binding protein
- SR9243 can also produce broad-spectrum anti-tumor effects by inhibiting glycolysis and lipogenesis in tumor cells.
- the LXR antagonists or inverse agonists can be developed and used as lead compounds for the treatment of hyperlipoidemia, fatty liver, obesity, diabetes, metabolic syndrome, and targeted tumor energy metabolism.
- Compounds that modulate the activity of liver X receptors are known from WO 2021/008014 A1 , WO 2016/100619 A2 , WO 2010/138598 A2 , and WO 2015/035015 A1 .
- liver X receptor regulator is provided.
- the new liver X receptor regulator can be effectively used to treat or prevent hyperlipidemia, fatty liver, obesity, diabetes, metabolic syndrome, or used to target at tumor energy metabolism, and also has significant therapeutic effects for cancers such as glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis and osteoporosis, having broad application prospects.
- the present disclosure provides a compound.
- the compound is a compound represented by formula (I), or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I), in which:
- the compound may further have at least one of the following additional technical features.
- R 4 , R 5 , and R 6 are each independently H, D, F, Cl, Br, I, -CN, -NO 2 , -OH, -NH 2 , -COOH, or C 1-4 alkyl; and R 7a , R 7b , R 7c , R 8 , R 8a , and R 8b are each independently H, D, F, Cl, Br, I, -CN, -NO 2 , -OH, -NH 2 , -COOH, C 1-4 alkyl, or C 1-4 halogenated alkyl.
- R 4 , R 5 , and R 6 are independently H, D, F, Cl, Br, I, -CN, -NO 2 , -OH, -NH 2 , -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, or n-butyl; and R 7a , R 7b , R 7c , R 8 , R 8a , and R 8b are each independently H, D, F, Cl, Br, I, -CN, -NO 2 , -OH, -NH 2 , -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, or 3,3,3-trifluoropropyl.
- the compound is a compound represented by represented by Formula (II-1-A), (II-1-B), or (II-1-C); or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (II-1-A), (II-1-B), or (II-1-C), in which:
- the compound represented by Formula (II-1-A) or (II-1-B) can effectively inversely activate liver X receptors, effectively treat or prevent hyperlipidemia, fatty liver, obesity, diabetes or metabolism syndrome, or it can be used to target tumor energy metabolism.
- the compound represented by Formula (II-1-C) can effectively activate liver X receptors, and effectively treat or prevent glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, osteoporosis, or a combination thereof.
- R 13a is H, D, F, Cl, Br, I, -CN, -NO 2 , -OH, -NH 2 , -COOH, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 1-4 halogenated alkyl, C 1-4 hydroxyl-substituted alkyl, C 1-4 alkoxyl, or C 1-4 halogenated alkoxy;
- R 13a is H, D, F, Cl, Br, I, -CN, -NO 2 , -OH, -NH 2 , -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, or 3,3,3-trihydroxyprop
- the compound is a compound represented by Formula (II-1-A-a), (II-1-A-b), (II-1-B-a), (II-1-B-b), (II-1-C-a), or (II-1-C-b), or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (II-1-A-a), (II-1-A-b), (II-1-B-a), (II-1-B-b), (II-1-C-a), or (II-1-C-b),
- the compound is a compound having one of the following structures, or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound having one of the following structures:
- the present disclosure provides a pharmaceutical composition including the aforementioned compound.
- the pharmaceutical composition may further have at least one of the following additional technical features.
- the pharmaceutical composition further includes a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, or any combinations thereof.
- the pharmaceutical composition further includes an additional therapeutic agent.
- the additional therapeutic agent is a medicament for treatment of hyperlipidemia, fatty liver, obesity, diabetes, metabolic syndrome, or a combination thereof.
- the additional therapeutic agent is a medicament for treatment of glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, or osteoporosis, or a combination thereof.
- the medicament for the treatment of hyperlipidemia, fatty liver, obesity, diabetes or metabolic syndrome is atorvastatin, gemfibrozil, acpimox, Eicosapentaenoic acid, metformin, glimepiride, repaglinide, empagliflozin, or any combination thereof.
- the medicament for the treatment of glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, or osteoporosis is temozolomide, fotemustine, statin, fibrate, trihexyphenidyl, aspirin, non-steroidal anti-inflammatory medicament, or any combination thereof.
- the statin is lovastatin or simvastatin; the fibrate is clofibrate, lifibrate or bezafibrate; and the non-steroidal anti-inflammatory medicament is diclofenac, nabumetone, or meloxicam.
- the above-mentioned compound or the above-mentioned pharmaceutical composition is for use in manufacture of a medicament.
- the medicament is used for treatment or prevention of hyperlipidemia, fatty liver, obesity, diabetes or metabolic syndrome, or for targeting at tumor energy metabolism; or the medicament is used for treatment or prevention of glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, osteoporosis or a combination thereof.
- Stereoisomers refer to compounds that have the same chemical structure but differ in the spatial arrangement of atoms or moieties. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis/trans isomers), atropisomers, etc.
- “Chirality” refers to a molecule that cannot overlap with its mirror image. “Achirality” refers to a molecule that can overlap with its mirror image.
- Enantiomers refer to two isomers of a compound that are each a mirror image of the other one but cannot overlap with each other.
- Diastereomers refer to stereoisomers that have two or more chiral centers and molecules of which are not mirror images of each other. Diastereomers have different physical properties such as melting point, boiling point, spectral properties and reactivity. A mixture of diastereomers can be separated by high-resolution analytical operations, for example, electrophoresis, and chromatography such as HPLC.
- optically active forms i.e., they are capable of rotating a plane of plane-polarized light.
- the prefixes D and L, or R and S are used to denote the absolute configurations of the molecule with respect to one or more chiral centers.
- the prefixes d and 1, or (+) and (-) are symbols used to specify a rotation of plane-polarized light caused by a compound, where (-) or 1 indicates that the compound is levorotatory, and the prefix (+) or d indicates that the compound is dextrorotatory.
- specific stereoisomers are enantiomers, and a mixture of such isomers is called an enantiomeric mixture.
- a mixture of enantiomers in 50:50 is called a racemic mixture or a racemate, which may occur when there is no stereoselectivity or stereospecificity in a chemical reaction or process.
- any asymmetric atom (for example, carbon, etc.) of the compound of the present disclosure can be present in a racemate- or enantiomer-enriched form, for example, present in (R)-, (S)-, or (R, S) -configuration.
- each asymmetric atom in terms of (R)- or (S) -configuration, has an enantiomeric excess of at least 50%, an enantiomeric excess of at least 60%, an enantiomeric excess of at least 70%, an enantiomeric excess of at least 80%, an enantiomeric excess of at least 90%, an enantiomeric excess of at least 95%, or an enantiomeric excess of at least 99%.
- the compounds of the present disclosure may be present as one of the possible isomers or a mixture thereof, such as a racemate and a mixture of diastereomers, depending on the number of asymmetric carbon atoms.
- the optically active (R)- or (S) -isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be in the E or Z configuration; and if the compound contains disubstituted cycloalkyl, the substituent of the cycloalkyl may have a cis or trans configuration.
- Any obtained mixture of stereoisomers can be separated into pure or substantially pure stereoisomers, enantiomers, diastereomers according to the differences in physical and chemical properties of components, for example, by chromatography and/or fractional crystallization process.
- racemate of the obtained end-product or intermediate can be resolved into optical enantiomers by methods known to those skilled in the art, for example, by separating the obtained diastereomeric salts. Racemic products can also be separated by chiral chromatography, such as high-performance liquid chromatography (HPLC) using chiral adsorbents. Particularly, the enantiomers can be prepared by asymmetric synthesis, for example, referring to " Enantiomers, Racemates and Resolutions", Jacques, et al., Wiley Interscience, New York, 1981 ; " Principles of Asymmetric Synthesis", 2nd Ed. Robert E.
- tautomer or "tautomeric form” refers to structural isomers that have different energies and can be interconverted by crossing a low energy barrier. If tautomerism is possible (for example, in solution), a chemical equilibrium of tautomers can be reached.
- protontautomer also known as prototropic tautomer
- Valence tautomer includes interconversion through recombination of some bonding electrons.
- ketone-enol tautomerization is interconversion of 2,4-pentanedione and 4-hydroxy-3-penten-2-one tautomeric isomers.
- tautomerism is phenol-ketone tautomerization.
- a specific example of phenol-ketone tautomerization is interconversion of 4-hydroxypyridine and pyridin-4(1H)-one tautomeric isomers. Unless otherwise indicated, all tautomeric forms of the compound of the present disclosure shall fall within the scope of the present disclosure.
- C 1 -C 6 alkyl specifically refers to independently disclosed methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, and C 6 alkyl.
- linking substituents are described.
- the Markush variables listed for the group should be understood as the linking group.
- the Markush group definition of the variable recites “alkyl” or “aryl”, it should be understood that the “alkyl” or “aryl” respectively represents the linking alkylene group or arylene group.
- the compounds of the present disclosure can be optionally substituted with one or more substituents, such as the compounds represented by the above general formulas, or particular examples, subclasses, and a type of compounds included in the present disclosure.
- substituents such as the compounds represented by the above general formulas, or particular examples, subclasses, and a type of compounds included in the present disclosure.
- substituents such as the compounds represented by the above general formulas, or particular examples, subclasses, and a type of compounds included in the present disclosure.
- substituents such as the compounds represented by the above general formulas, or particular examples, subclasses, and a type of compounds included in the present disclosure.
- alkyl used in the present disclosure includes linear or branched saturated monovalent hydrocarbyl group of 1-20 carbon atoms, where the alkyl can be independently and optionally substituted with one or more substituents described in the present disclosure.
- the alkyl group contains 1-10 carbon atoms; in some other embodiments, the alkyl group contains 1-8 carbon atoms; in some other embodiments, the alkyl group contains 1-6 carbon atoms; in some other embodiments, the alkyl group contains 1-4 carbon atoms; in some other embodiments, the alkyl group contains 1-3 carbon atoms; and in some other embodiments, the alkyl group contains 2-6 carbon atoms.
- alkyl group examples include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), n-propyl (n-Pr, - CH 2 CH 2 CH 3 ), isopropyl (i-Pr, -CH(CH 3 ) 2 ), n-butyl (n-Bu, -CH 2 CH 2 CH 2 CH 3 ), 2-methylpropyl or isobutyl (i-Bu, -CH 2 CH(CH 3 ) 2 ), 1-methylpropyl or sec-butyl (s-Bu, -CH(CH 3 )CH 2 CH 3 ), tert-butyl (t-Bu, -C(CH 3 ) 3 ), n-pentyl (-CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (-CH(CH 3 )CH 2 CH 2 CH 3 ), 3-pentyl(-CH(CH 2 CH 3 ) 2 ), 2-
- halogenated alkyl refers to that alkyl may be substituted with one or more identical or different halogen atoms, which are F, Cl, Br, or I.
- the alkyl group has the meaning as described in the present disclosure, and examples thereof include, but are not limited to, totrifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, etc.
- hydroxyl-substituted alkyl refers to that alkyl may be substituted with one or more hydroxyl groups.
- the alkyl group has the meaning as described in the present disclosure, and examples thereof include, but are not limited to, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, etc.
- amino refers to -NH 2 .
- alkoxy used in the present disclosure involves alkyl, as defined in the present disclosure, connected to a main carbon chain through an oxygen atom.
- alkyl as defined in the present disclosure, connected to a main carbon chain through an oxygen atom.
- examples include, but are not limited to, methoxyl, ethoxy, propoxy, and the like.
- cycloalkyl refers to a monovalent or multivalent saturated monocyclic, bicyclic or tricyclic ring system containing 3-12 carbon atoms.
- the bicyclic or tricyclic ring system may include fused rings, bridged rings, and spiro rings.
- cycloalkyl contains 3-10 carbon atoms; in another embodiment, cycloalkyl contains 3-8 carbon atoms; in another embodiment, cycloalkyl contains 3-6 carbon atoms.
- Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
- the cycloalkyl group is optionally substituted with one or more substituents described in the present disclosure.
- aryl refers to a monocyclic, bicyclic and tricyclic carbon ring system containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, at least one ring of which is aromatic.
- the aryl group is usually, but not necessarily, connected to the core moiety through the aromatic ring of the aryl group.
- aryl can be used interchangeably with the term “aromatic ring”. Examples of the aryl may include phenyl, naphthyl, and anthracyl.
- the aryl group is optionally substituted with one or more substituents described in the present disclosure.
- heteromatic ring refers to a monocyclic, bicyclic and tricyclic ring system containing 5-12 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms, at least one ring of which is aromatic and at least one ring of which contains one or more heteroatoms.
- the heteroaromatic ring is usually, but not necessarily, connected to the core moiety through the aromatic ring of the heteroaromatic ring.
- heteroaryl can be used interchangeably with the term “heteroaromatic ring", “aromatic heterocyclic ring", or “heteroaromatic compound”.
- the heteroaryl group is optionally substituted with one or more substituents described in the present disclosure.
- the heteroaryl group consisting of 5 to 10 atoms, contains 1, 2, 3, or 4 heteroatoms independently selected from O, S, or N.
- heteroaryl examples include, but are not limited to, 2-finyl, 3-furyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (such as 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (such as 5-tetrazolyl), triazolyl (such as 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (such as
- heteroaryl further include, but not limited to, the following bicyclic rings: benzimidazolyl, benzofuranyl, benzothienyl, indolyl (such as 2-indolyl), purinyl, quinolinyl (such as 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), isoquinolinyl (such as 1-isoquinolinyl, 3-isoquinolinyl or 4-isoquinolinyl), imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridyl,
- a ring system with a substituent R' connected to a core ring of the ring system through one bond represents that the substituent R' can be substituted at any substitutable or any suitable position on the ring.
- formula a represents that any substitutable position on the B' ring can be substituted with R', e.g., shown in formula b, formula c and formula d.
- pharmaceutically acceptable refers to molecular entities and compositions that are physiologically tolerable when administered to humans and generally do not produce allergies or similar inappropriate reactions, such as gastrointestinal discomfort, dizziness, and the like.
- pharmaceutically acceptable refers to those approved by a federal regulatory agency or a national government or recorded in the US Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, more particularly in humans.
- carrier refers to a diluent, adjuvant, excipient or matrix that is administered together with the compound.
- These pharmaceutical carriers can be sterile liquids such as water and oils, including those derived from petroleum, animals, plants, or synthetic sources, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, aqueous saline solution, aqueous dextrose, and glycerite are preferably used as carriers, especially for injectable solutions. Suitable carriers of medicaments are described in "Remington's Pharmaceutical Sciences", by E. W. Martin.
- the "hydrate” of the present disclosure refers to the compound or its salt provided by the present disclosure with chemical or non-chemical equivalent water bonded thereto by non-covalent intermolecular force, i.e., an associated complex formed when the solvent molecule is water.
- the "solvate” of the present disclosure refers to an associated complex formed by one or more solvent molecules and the compound of the present disclosure.
- the solvents for forming the solvate include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol.
- esters in the present disclosure refers to esters that are formed by the compounds represented by Formula (I) to Formula (IV) containing hydroxyl and can be hydrolyzed in vivo.
- esters are, for example, pharmaceutically acceptable esters that are hydrolyzable in the human or animal body to produce alcohols.
- the in vivo hydrolyzable esters of the compounds represented by Formula (I) to Formula (IV) containing hydroxyl include, but are not limited to, phosphate group, acetyloxymethoxyl, 2,2-dimethyl acetyloxymethoxyl, alkanoyl, benzoyl, benzylacetyl, alkoxycarbonyl, dialkylcarbamoyl, and N-(dialkylaminoethyl)-N-alkylcarbamoyl, etc.
- N-oxide means that, when the compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxide.
- N-oxides are N-oxides of tertiary amines or N-oxides of the nitrogen atom of nitrogen heterocycle.
- An oxidant such as hydrogen peroxide or peracid (such as peroxycarboxylic acid) can be used to process a corresponding amine to form N-oxide (see Advanced Organic Chemistry, Wiley Interscience, 4th edition, Jerry March, pages ).
- N-oxides can be prepared by the method by L. W. Deady (Syn. Comm. 1977, 7, 509-514 ), in which, for example, the amine compound reacts with m-chloroperoxybenzoic acid (MCPBA) in an inert solvent such as dichloromethane.
- MCPBA m-chloroperoxybenzoic acid
- prodrug used in the present disclosure indicates a compound that is converted into a compound represented by formula (I) in vivo. Such conversion is affected by a prodrug hydrolysis in blood or an enzymatic conversion into a parent structure in blood or tissues.
- the prodrug compounds of the present disclosure may be esters.
- the esters serving as prodrugs include phenyl esters, aliphatic (C 1-24 ) esters, acyloxymethyl esters, carbonate esters, carbamate esters and amino acid esters.
- a compound in the present disclosure contains hydroxyl, which can be acylated to obtain a compound in the form of a prodrug.
- prodrug examples include phosphate esters, for example, the phosphate ester compounds obtained by phosphorylation of the hydroxyl group on the parent structure.
- phosphate esters for example, the phosphate ester compounds obtained by phosphorylation of the hydroxyl group on the parent structure.
- prodrugs please refer to the following literatures: T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, Edward B. Roche, ed ., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987 , J. Rautio et al., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270 , and S. J. Hecker et al., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry, 2008, 51, 2328-2345 . Prodrugs are not part of the invention.
- the structural formulas of the compounds described in the present disclosure include enriched isotopes of one or more different atoms, unless otherwise indicated.
- the present disclosure includes isotopically-labeled compounds, which are equivalent to the compounds represented by formula (I) to formula (II), but one or more atoms thereof are replaced by atoms with atomic mass or mass number different from the common atomic mass or mass number in nature.
- isotopes that can be introduced in the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H, 3 H, 13 C, 11 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F and 36 Cl.
- the compounds of the present disclosure containing the above isotopes and/or other isotopes of other atoms, and pharmaceutically acceptable salts of the compounds or the prodrugs all fall within the scope of the present disclosure.
- the isotopically-labeled compounds of formula (I) to formula (II) of the present disclosure and their prodrugs can generally be prepared in this way: when performing the following procedures and/or the processes disclosed in the examples and preparation examples, the non-isotopically labeled reagents are replaced by the isotopically-labeled reagents that are easily available.
- Methodabolite refers to a product obtained by metabolizing a specific compound or its salt in vivo.
- the metabolite of one compound can be identified by techniques well known in the art, and its activity can be characterized by assays as described in the present disclosure.
- Such a product may be obtained through oxidation, reduction, hydrolysis, amidation, deamidation, esterification, degreasing, or enzyme cleavage of the administrated compound, or the like.
- the present disclosure includes the metabolites of the compound, including metabolites produced by fully contacting the compound of the present disclosure with a mammal for a period of time. Metabolites are not part of the invention.
- compositions can be prepared from an active component and a pharmaceutically acceptable carrier.
- a "pharmaceutically acceptable salt” refers to an organic or inorganic salt of the compound of the present disclosure.
- the pharmaceutically acceptable salts are well known in the art, as described in the literature: S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19, 1977 .
- Salts formed by pharmaceutically acceptable non-toxic acids include, but are not limited to, inorganic acid salts formed by reacting with amino groups, including hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, nitrate, etc.; and organic acid salts such as acetate, propionate, glycollate, oxalate, maleate, malonate, succinate, fumarate, tartrate, citrate, benzoate, mandelate, methanesulfonate, ethanesulfonate, tosylate, sulfosalicylate, etc., or the salts obtained through other methods such as ion exchange described in book literatures.
- inorganic acid salts formed by reacting with amino groups including hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, nitrate, etc.
- organic acid salts such as acetate, propionate, glycollate, oxalate, maleate,
- salts include adipate, malate, 2-hydroxypropionic acid, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentylpropionate, digluconate, dodecyl sulfate, esilate, formate, fumarate, gluceptate, glycerophosphate, gluconate, hemisulphate, enanthate, caproate, hydriodate, 2-hydroxy-ethanesulfonate, lactobionic acid salt, lactate, laurate, lauryl sulfate, malate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulfate, 3-phenylpropionat
- the present disclosure also contemplates quaternary ammonium salts formed by any compound with a group containing N.
- Water-soluble or oil-soluble or dispersed products can be obtained by quaternization.
- the salts of alkali metal or alkaline earth metal include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, etc.
- the pharmaceutically acceptable salts further include suitable and non-toxic ammoniums, quaternary ammonium salts and amine cations formed by counterions, such as halides, hydroxides, carboxylates, hydrosulfates, phosphates, nitrates, C 1-8 sulfonates and aromatic sulfonates.
- ammonium salts such as but not limited to N, N'-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methyl glucosamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1'-ylmethyl-benzimidazole, diethylamine and other alkylamines, piperazine, and tris(hydroxymethyl)aminomethane; alkaline earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, for example, including, but not limited to zinc.
- alkaline earth metal salts such as but not limited to barium, calcium and magnesium
- transition metal salts for example, including, but not limited to zinc.
- the structure shall prevail if the chemical name is different from the chemical structure.
- a first aspect of the present disclosure provides a new compound having a significant regulatory activity for liver X receptors.
- a second aspect of the present disclosure provides a new compound that has significant therapeutic effects on hyperlipidemia, fatty liver, obesity, diabetes, and metabolic syndrome, and can target at tumor energy metabolism.
- a third aspect of the present disclosure provides a method for preparing the liver X receptor regulator.
- the present disclosure provides a method for preparing the 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver X receptor regulator.
- the method includes the following steps: dissolving tryptamine and isobutyraldehyde in dichloromethane and performing a Pictet-Spengler reaction in an acidic environment to obtain an intermediate 1a; dissolving the intermediate 1a in tetrahydrofuran for rearrangement under the presence of N-bromosuccinimide, so as to obtain an intermediate 1b; dissolving the intermediate 1b in dichloromethane, and adding triethylamine to react with di-tert-butyl decarbonate, so as to obtain an intermediate 1c; dissolving the intermediate 1c in toluene, and adding cuprous iodide, N,N-dimethylethylenediamine, and potassium carbonate to react with m-chloroiodobenzene to obtain an intermediate 1d; dissolving
- the compound provided by the present disclosure has a significant regulatory activity for the liver X receptor and lipid-lowering activity, and thus it can be used as a lead compound for treatment of hyperlipidemia, fatty liver, obesity, diabetes, and metabolic syndrome and for targeting at tumor energy metabolism.
- liver X receptor regulators are screened from the compounds provided by the present disclosure.
- the lipid-lowering activities of the compounds in hepatocytes and adipocytes are tested on HepG2 cells and 3T3-L1 cells. It was found that compound 2a-1 has the best regulatory activity for the liver X receptor and lipid-lowering activity, and the lipid-lowering mechanism thereof has been investigated. The results indicate that this compound exerts the lipid-lowering effect by down-regulating liver X receptor downstream genes SREBP-1c, ACC, FAS, SCD-1. At the same time, compound 2a-1 also has lipid-lowering activity in a mice hyperlipidemia model induced by Triton WR-1339.
- the compounds provided by the present disclosure require raw materials that are easily available, can be easily prepared, and have the significant regulatory activity for liver X receptor and lipid-lowering activity.
- the 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver X receptor regulator exerts the lipid-lowering effect by down-regulating the liver X receptor downstream genes SRFBP-1c, ACC, FAS, and SCD-1. Accordingly, the compounds of the present disclosure have great application prospects in the preparation of drugs for prevention and treatment of hyperlipidemia, fatty liver, obesity, diabetes, metabolic syndrome, and tumors.
- Example 2 Liver X receptor activity test of the compounds obtained in Example 1
- the liver X receptor inverse agonist activity of the compounds is shown in Table 1.
- Table 1 By analyzing Table 1, it can be found that compounds 2a, 2a-1, 2a-2, 2b, 2c, 2d, etc. can inversely activate liver X receptors. Among them, compound 2a-1 has the best inverse agonist activity, and thus it was used for the study of lipid-lowering activity and mechanism.
- the liver X receptor agonist activities of the compounds are shown in Table 2. From Table 2, it can be seen that compounds 3a, 3b, and 3c can activate liver X receptors.
- Example 3 Study on lipid-lowering activity of compound 2a-1 obtained in Example 1 in HepG2 cells and 3T3-L1 cells
- the detection results of the triglyceride content indicate that, at a concentration of 10 ⁇ M, the compound 2a-1 can significantly reduce the triglyceride accumulation in HepG2 cells induced by high glucose. In addition, the compound 2a-1 lowers the triglyceride level in 3T3-L1 cells in a concentration-dependent manner, with an IC 50 of 0.27 ⁇ 0.03 ⁇ M.
- the above results substantiate that the compound 2a-1 has significant lipid-lowering activity in HepG2 cells and 3T3-L1 cells.
- Example 4 Study on lipid-lowering activity of compound 2a-1 obtained in Example 1 in HepG2 cells and 3T3-L1 cells
- HepG2 cells were seeded in a 6-well plate with a cell density of 8 ⁇ 10 5 cells/well and incubated for 24 hours. The compounds to be tested were added and acted for 24 hours, and then the cells were harvested. The 3T3-L1 cells were harvested on day 6 of differentiation. The cells were washed twice with PBS, total RNA was extracted with RNAiso plus reagent, 1 ⁇ g of total RNA was reverse transcribed into cDNA using ReverTra Ace qPCR RT Master Mix, and PCR amplification was performed using SYBR Green Realtime PCR Master Mix.
- the compound 2a-1 reduced the mRNA content of SREBP-1c, ACC, FAS and SCD-1 in a concentration-dependent manner.
- the compound 2a-1 significantly reduced the mRNA content of these four genes. The above results prove that the compound 2a-1 can inhibit the expressions of SREBP-1c, ACC, FAS, and SCD-1 in 3T3-L1 cells and HepG2 cells, thereby inhibiting fat synthesis.
- Example 5 Study on lipid-lowering activity of compound 2a-1 obtained in Example 1 in Triton WR-1339-induced hyperlipidemia mice
- mice 6-week-old SPF female C57BL/6J mice were purchased from the Experimental Animal Center of Sun Yat-sen University. The mice were randomly divided into 4 groups each including 6 mice, i.e., a normal control group, model a group, a fenofibrate group (100 mg/kg), and a B1 group (100 mg/kg), and intragastric administration was performed for 8 days. 24 hours before the last administration, the normal control group was intramuscularly injected with saline, and the remaining groups were injected with Triton WR-1339 (1500 mg/kg). One hour after the last administration, the eyeballs were removed to collect blood, the mice were executed by cervical dislocation, and the livers were collected.
- a normal control group model a group
- a fenofibrate group 100 mg/kg
- B1 group 100 mg/kg
- intragastric administration was performed for 8 days. 24 hours before the last administration, the normal control group was intramuscularly injected with saline, and the remaining groups were
- the plasma was allowed to stand for 1 hour, and the supernatant was collected by centrifugation at 4 °C and 3000 rpm.
- 100 mg of liver was weighed, added with methanol in 3 times the volume of the weighed liver, and homogenized thoroughly. Chloroform was then added in 6 times the volume and vortex oscillated. After centrifuging at 3000 rpm for 10 minutes, the lower chloroform layer was collected, and evaporated naturally overnight in a fume hood. 150 ⁇ L of 1% Triton ethanol was added and heated at 65°C to be fully dissolved. Finally, triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in serum and liver samples were detected.
- TG total cholesterol
- LDL-C low-density lipoprotein cholesterol
- HDL-C high-density lipoprotein cholesterol
- the positive drug, fenofibrate and compound 2a-1 can significantly inhibit the increases in TG level, TC level, LDL-C level, and HDL-C level that are induced by Triton WR-1339.
- Neither fenofibrate nor compound 2a-1 had a significant effect on HDL-C/TC, but compound 2a-1 slightly increased HDL-C/LDL-C level.
- the above results indicate that the compound 2a-1 can significantly reduce the blood lipid levels in the Triton WR-1339-induced hyperlipidemia mice.
- compound 2a-1 can reduce the triglyceride content in the livers of mice. There were no significant differences in liver cholesterol levels between the groups.
- the above results indicate that compound 2a-1 can significantly reduce the accumulation of triglycerides in the livers of Triton WR-1339-induced hyperlipidemia mice.
- compound 2a-1 also has significant lipid-lowering activity in mice.
- the compound of the present disclosure has the significant inverse agonist activity for the liver X receptor, and can inhibit the expressions of target genes SREBP-1c, ACC, FAS and SCD-1 of liver X receptors to have lipid-lowering effect. Therefore, the compound of the present disclosure can be used as a lead compound for the treatment of hyperlipidemia, fatty liver, obesity, diabetes, and metabolic syndrome and for targeting tumor energy metabolism.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
- The present disclosure relates to the field of biomedicines. Specifically, the present disclosure relates to a 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver X receptor regulator, a preparation method therefor, and uses thereof.
- Liver X receptor (LXR) is a ligand-dependent transcription factor that usually forms a heterodimer in a form of LXR/RXR together with retinol X receptor (RXR). Under the premise of ligand activation, LXR can be bonded to an LXR response element (LXRE) on the target gene to regulate a transcription process of the target gene. LXR includes two subtypes, i.e., LXRα and LXRβ. LXRα is distributed in liver, small intestine, adipose tissue, and macrophages with immune functions, while LXRβ is widely distributed throughout the body.
- LXR is a nuclear receptor activated by oxysterols, and plays an important role in fat, cholesterol, and sugar metabolisms, and inflammation. It has broad development prospects to develop new drugs targeting at LXR. The synthetic LXR agonists include GW3965 and TO901317, etc. The LXR agonists can be developed and used as lead compounds for the treatment of atherosclerosis, cancer, Alzheimer's disease, atopic dermatitis, and other diseases.
- At present, there are few LXR antagonists or inverse agonists, mainly including SR9243, SR9238, PP2P, fenofibrate, morin, and luteolin, etc. Many articles have indicated that LXR antagonists or inverse agonists have strong anti-fatty liver activity. Among them, the mechanism of LXR antagonists or inverse agonists for lipid-lowering is to down-regulate sterol regulatory element-binding protein (SREBP-1c) of LXR target gene, acetyl-coA carboxylase (ACC), lipese (FAS), and stearoyl-CoA desaturase-1 (SCD-1), so as to reduce triglyceride synthesis. In addition, SR9243 can also produce broad-spectrum anti-tumor effects by inhibiting glycolysis and lipogenesis in tumor cells. The LXR antagonists or inverse agonists can be developed and used as lead compounds for the treatment of hyperlipoidemia, fatty liver, obesity, diabetes, metabolic syndrome, and targeted tumor energy metabolism. Compounds that modulate the activity of liver X receptors are known from
WO 2021/008014 A1 ,WO 2016/100619 A2 ,WO 2010/138598 A2 , andWO 2015/035015 A1 . An article by Nakazaki Atsuo et. al. also discloses modulators of the activity of LXR (see Nakazaki Atsuo, Mori Ayako, Kobayashi Susumu, Nishikawa Toshio: "Diastereoselective synthesis of 3,3-disubstituted oxindoles from atmpisomeric N-aryl oxindole derivatives", Tetrahedron Letters, vol. 53, no. 52, December 1, 2012, pages 7131-7134). - The present disclosure is based on the following facts and problems that are found and recognized by the applicant.
- Through a large number of experimental studies, a new liver X receptor regulator is provided. The applicant surprisingly found that it has a significant regulatory activity for liver X receptors. The new liver X receptor regulator can be effectively used to treat or prevent hyperlipidemia, fatty liver, obesity, diabetes, metabolic syndrome, or used to target at tumor energy metabolism, and also has significant therapeutic effects for cancers such as glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis and osteoporosis, having broad application prospects.
- In a first aspect of the present disclosure, the present disclosure provides a compound. The compound is a compound represented by formula (I), or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by formula (I),
- X1, X2 are independently C(R7a)2;
- R1 is H, D, F, Cl, Br, I, -CN, -NOz, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, C1-6 halogenated alkoxyl, -C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, - NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, R7bS(=O)2-, C6-10 aryl, or heteroaryl consisting of 5-12 atoms, wherein one, two, three, four or five carbon atoms of the C6-10 aryl or heteroaryl consisting of 5-12 atoms are independently and optionally substituted with R10;
- each R10 is each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, C1-6 halogenated alkoxyl, -C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, or R7bS(=O)2-;
- R2 is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, -C(=O)NR8aR8b, - C(=S)NR8aR8b, -NR8C(=O)R7c, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7c, or R7cS(=O)2-;
- R3 is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, oxo, or C1-6 alkyl;
- R4, R5, and R6 are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, or C1-6 alkyl;
- R7a, R7b, R7c, R8, R8a, and R8b are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, or C1-6 halogenated alkyl; and
- m1, m2, and n1 are independently 0, 1, 2, 3, or 4.
- According to an embodiment of the present disclosure, the compound may further have at least one of the following additional technical features.
- According to an embodiment of the present disclosure, R1 is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, C1-4 halogenated alkoxyl, - C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, - R8N-S(=O)2R7b, R7bS(=O)2-, C6-10 aryl, or heteroaryl consisting of 5-10 atoms, where one, two, three, four or five carbon atoms of the C6-10 aryl or heteroaryl consisting of 5-10 atoms are independently and optionally substituted with R10; and R10 is each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, C1-4 halogenated alkoxyl, - C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, - R8N-S(=O)2R7b, or R7bS(=O)2-.
- According to an embodiment of the present disclosure, R1 is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, - C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, - R8N-S(=O)2R7b, R7bS(=O)2-, C6-10 aryl, or heteroaryl consisting of 5-10 atoms, where one, two, three, four or five carbon atoms of the C6-10 aryl or heteroaryl consisting of 5-10 atoms are independently and optionally substituted with R10; and R10 is each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, - C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, - R8N-S(=O)2R7b, or R7bS(=O)2-.
- According to an embodiment of the present disclosure, R4, R5, and R6 are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, or C1-4 alkyl; and R7a, R7b, R7c, R8, R8a, and R8b are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, or C1-4 halogenated alkyl.
- According to an embodiment of the present disclosure, R4, R5, and R6 are independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, or n-butyl; and R7a, R7b, R7c, R8, R8a, and R8b are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, or 3,3,3-trifluoropropyl.
- According to an embodiment of the present disclosure, the compound is a compound represented by Formula (II-1) or Formula (II-2); or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (II-1) or Formula (II-2),
R11, R12, R13, R14, or R15 is independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, - COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, C1-6 halogenated alkoxyl, -C(=O)R7b, -C(=O)OR7b, - OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, or R7bS(=O)2-. - According to an embodiment of the present disclosure, R11, R12, R13, R14, or R15 is independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, C1-4 halogenated alkoxyl, -C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, - NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, or R7bS(=O)2-.
- According to an embodiment of the present disclosure, R11, R12, R13, R14, or R15 is independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, -C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, - NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, or R7bS(=O)2-.
- According to an embodiment of the present disclosure, the compound is a compound represented by represented by Formula (II-1-A), (II-1-B), or (II-1-C); or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (II-1-A), (II-1-B), or (II-1-C),
- R2a is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, or R7cS(=O)2-; R12a is R7bS(=O)2-; and R13a is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, or C1-6 halogenated alkoxy;
- R2b is R7cS(=O)2-; and R12b and R13b are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, C1-6 halogenated alkoxyl, -C(=O)R7b, - C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, or -NR8C(=O)R7b; and
- R2c is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, -C(=S)NR8aR8b, - C(=O)NR8aR8b, or -NR8C(=O)R7c; R12c is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, or C1-6 halogenated alkoxy; and R13c is -C(=O)NR8aR8b, or - NR8C(=O)R7b.
- The applicant found that the compound represented by Formula (II-1-A) or (II-1-B) can effectively inversely activate liver X receptors, effectively treat or prevent hyperlipidemia, fatty liver, obesity, diabetes or metabolism syndrome, or it can be used to target tumor energy metabolism. In addition, the applicant found that the compound represented by Formula (II-1-C) can effectively activate liver X receptors, and effectively treat or prevent glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, osteoporosis, or a combination thereof.
- According to an embodiment of the present disclosure, R2a is -C(=O)R7c, - C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, or R7cS(=O)2-; R12a is R7bS(=O)2-; and R13a is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, or C1-4 halogenated alkoxy;
- R2b is R7cS(=O)2-; and R12b and R13b are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, C1-4 halogenated alkoxyl, -C(=O)R7b, - C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, or -NR8C(=O)R7b; and
- R2c is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, -C(=S)NR8aR8b, - C(=O)NR8aR8b, or -NR8C(=O)R7c; R12c is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, or C1-4 halogenated alkoxy; and R13c is -C(=O)NR8aR8b, or - NR8C(=O)R7b.
- According to an embodiment of the present disclosure, R2a is -C(=O)R7c, - C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, or R7cS(=O)2-; R12a is R7bS(=O)2-; and R13a is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, or 3,3,3-trihydroxypropyl;
- R2b is R7cS(=O)2-; and R12b and R13b are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, -C(=O)R7b, - C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, or -NR8C(=O)R7b; and
- R2c is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, -C(=S)NR8aR8b, - C(=O)NR8aR8b, or -NR8C(=O)R7c; R12c is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxy ethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl; and R13c is -C(=O)NR8aR8b, or - NR8C(=O)R7b.
- According to an embodiment of the present disclosure, the compound is a compound represented by Formula (II-1-A-a), (II-1-A-b), (II-1-B-a), (II-1-B-b), (II-1-C-a), or (II-1-C-b), or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (II-1-A-a), (II-1-A-b), (II-1-B-a), (II-1-B-b), (II-1-C-a), or (II-1-C-b),
- According to an embodiment of the present disclosure, the compound is a compound having one of the following structures, or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound having one of the following structures:
- In a second aspect of the present disclosure, the present disclosure provides a pharmaceutical composition including the aforementioned compound.
- According to an embodiment of the present disclosure, the pharmaceutical composition may further have at least one of the following additional technical features.
- According to an embodiment of the present disclosure, the pharmaceutical composition further includes a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle, or any combinations thereof.
- According to an embodiment of the present disclosure, the pharmaceutical composition further includes an additional therapeutic agent. In some embodiments, the additional therapeutic agent is a medicament for treatment of hyperlipidemia, fatty liver, obesity, diabetes, metabolic syndrome, or a combination thereof. In other embodiments, the additional therapeutic agent is a medicament for treatment of glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, or osteoporosis, or a combination thereof.
- According to an embodiment of the present disclosure, the medicament for the treatment of hyperlipidemia, fatty liver, obesity, diabetes or metabolic syndrome is atorvastatin, gemfibrozil, acpimox, Eicosapentaenoic acid, metformin, glimepiride, repaglinide, empagliflozin, or any combination thereof.
- According to an embodiment of the present disclosure, the medicament for the treatment of glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, or osteoporosis is temozolomide, fotemustine, statin, fibrate, trihexyphenidyl, aspirin, non-steroidal anti-inflammatory medicament, or any combination thereof. In some embodiments, the statin is lovastatin or simvastatin; the fibrate is clofibrate, lifibrate or bezafibrate; and the non-steroidal anti-inflammatory medicament is diclofenac, nabumetone, or meloxicam.
- In a third aspect of the present disclosure, the above-mentioned compound or the above-mentioned pharmaceutical composition is for use in manufacture of a medicament. The medicament is used for treatment or prevention of hyperlipidemia, fatty liver, obesity, diabetes or metabolic syndrome, or for targeting at tumor energy metabolism; or the medicament is used for treatment or prevention of glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, osteoporosis or a combination thereof.
-
-
FIG. 1 is a schematic diagram illustrating a lipid-lowering activity ofCompound 2a-1 according to an embodiment of the present disclosure in HepG2 cells and a mechanism thereof; -
FIG. 2 is a schematic diagram illustrating a lipid-lowering activity ofCompound 2a-1 according to an embodiment of the present disclosure in 3T3L1 cells and a mechanism thereof; and -
FIG. 3 illustrates a lipid-lowering activity ofCompound 2a-1 according to an embodiment of the present disclosure in mice with hyperlipidemia induced by Triton WR-1339. - Embodiments of the present disclosure are described in detail below, and examples of the embodiments are shown in the accompanying drawings. The embodiments described below with reference to the accompanying drawings are illustrative, which aims to explain the present disclosure, but should not be interpreted as limiting the present disclosure.
- The term "include" or "comprise" is an open-ended expression, i.e., including the content specified in the present disclosure but not excluding the content in other aspects.
- "Stereoisomers" refer to compounds that have the same chemical structure but differ in the spatial arrangement of atoms or moieties. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis/trans isomers), atropisomers, etc.
- "Chirality" refers to a molecule that cannot overlap with its mirror image. "Achirality" refers to a molecule that can overlap with its mirror image.
- "Enantiomers" refer to two isomers of a compound that are each a mirror image of the other one but cannot overlap with each other.
- "Diastereomers" refer to stereoisomers that have two or more chiral centers and molecules of which are not mirror images of each other. Diastereomers have different physical properties such as melting point, boiling point, spectral properties and reactivity. A mixture of diastereomers can be separated by high-resolution analytical operations, for example, electrophoresis, and chromatography such as HPLC.
- The definitions and rules of stereochemistry used in the present disclosure generally follow "McGraw-Hill Dictionary of Chemical Terms (1984)", S. P. Parker, Ed., McGraw-Hill Book Company, New York; and "Stereochemistry of Organic Compounds", Eliel, E. and Wilen, S., John Wiley & Sons, Inc., New York, 1994.
- Many organic compounds exist in optically active forms, i.e., they are capable of rotating a plane of plane-polarized light. When describing optically active compounds, the prefixes D and L, or R and S are used to denote the absolute configurations of the molecule with respect to one or more chiral centers. The prefixes d and 1, or (+) and (-) are symbols used to specify a rotation of plane-polarized light caused by a compound, where (-) or 1 indicates that the compound is levorotatory, and the prefix (+) or d indicates that the compound is dextrorotatory. When specific stereoisomers are enantiomers, and a mixture of such isomers is called an enantiomeric mixture. A mixture of enantiomers in 50:50 is called a racemic mixture or a racemate, which may occur when there is no stereoselectivity or stereospecificity in a chemical reaction or process.
- Any asymmetric atom (for example, carbon, etc.) of the compound of the present disclosure can be present in a racemate- or enantiomer-enriched form, for example, present in (R)-, (S)-, or (R, S)-configuration. In some embodiments, in terms of (R)- or (S)-configuration, each asymmetric atom has an enantiomeric excess of at least 50%, an enantiomeric excess of at least 60%, an enantiomeric excess of at least 70%, an enantiomeric excess of at least 80%, an enantiomeric excess of at least 90%, an enantiomeric excess of at least 95%, or an enantiomeric excess of at least 99%.
- In accordance with the selection of starting materials and methods, the compounds of the present disclosure may be present as one of the possible isomers or a mixture thereof, such as a racemate and a mixture of diastereomers, depending on the number of asymmetric carbon atoms. The optically active (R)- or (S)-isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be in the E or Z configuration; and if the compound contains disubstituted cycloalkyl, the substituent of the cycloalkyl may have a cis or trans configuration.
- Any obtained mixture of stereoisomers can be separated into pure or substantially pure stereoisomers, enantiomers, diastereomers according to the differences in physical and chemical properties of components, for example, by chromatography and/or fractional crystallization process.
- The racemate of the obtained end-product or intermediate can be resolved into optical enantiomers by methods known to those skilled in the art, for example, by separating the obtained diastereomeric salts. Racemic products can also be separated by chiral chromatography, such as high-performance liquid chromatography (HPLC) using chiral adsorbents. Particularly, the enantiomers can be prepared by asymmetric synthesis, for example, referring to "Enantiomers, Racemates and Resolutions", Jacques, et al., Wiley Interscience, New York, 1981; "Principles of Asymmetric Synthesis", 2nd Ed. Robert E. Gawley, Jeffrey Aubé, Elsevier, Oxford, UK, 2012; "Stereochemistry of Carbon Compounds", Eliel, E.L., McGraw-Hill, NY, 1962; "Tables of Resolving Agents and Optical Resolutions", p. 268, Wilen, S.H., E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, in 1972; and "Chiral Separation Techniques: A Practical Approach", Subramanian, G. Ed., Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2007.
- The term "tautomer" or "tautomeric form" refers to structural isomers that have different energies and can be interconverted by crossing a low energy barrier. If tautomerism is possible (for example, in solution), a chemical equilibrium of tautomers can be reached. For example, protontautomer (also known as prototropic tautomer) includes interconversion through proton migration, such as ketone-enol isomerization and imine-enamine isomerization. Valence tautomer includes interconversion through recombination of some bonding electrons. A specific example of ketone-enol tautomerization is interconversion of 2,4-pentanedione and 4-hydroxy-3-penten-2-one tautomeric isomers. Another example of tautomerism is phenol-ketone tautomerization. A specific example of phenol-ketone tautomerization is interconversion of 4-hydroxypyridine and pyridin-4(1H)-one tautomeric isomers. Unless otherwise indicated, all tautomeric forms of the compound of the present disclosure shall fall within the scope of the present disclosure.
- In each part of the present specification, the substituents of the compounds disclosed in the present disclosure are disclosed according to the group types or ranges. In particular, the present disclosure includes each independent sub-combination of respective members within these group types and ranges. For example, the term "C1-C6 alkyl" specifically refers to independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl.
- In each part of the present disclosure, linking substituents are described. When the structure clearly requires a linking group, the Markush variables listed for the group should be understood as the linking group. For example, if the structure requires a linking group and the Markush group definition of the variable recites "alkyl" or "aryl", it should be understood that the "alkyl" or "aryl" respectively represents the linking alkylene group or arylene group.
- As described in the present disclosure, the compounds of the present disclosure can be optionally substituted with one or more substituents, such as the compounds represented by the above general formulas, or particular examples, subclasses, and a type of compounds included in the present disclosure. It should be understood that the term "optionally substituted" and the term "substituted or unsubstituted" are interchangeably used. Generally speaking, the term "optionally", whether it precedes the term "substituted", means that one or more hydrogen atoms in a given structure may be substituted or unsubstituted by specific substituents. Unless otherwise indicated, an optionally substituted group may have a substituent substituted at each substitutable position of the group. When more than one position in the given structural formula can be substituted by one or more substituents selected from specific groups, the substituents substituted at the respective positions can be the same or different from each other.
- The term "alkyl" used in the present disclosure includes linear or branched saturated monovalent hydrocarbyl group of 1-20 carbon atoms, where the alkyl can be independently and optionally substituted with one or more substituents described in the present disclosure. In some embodiments, the alkyl group contains 1-10 carbon atoms; in some other embodiments, the alkyl group contains 1-8 carbon atoms; in some other embodiments, the alkyl group contains 1-6 carbon atoms; in some other embodiments, the alkyl group contains 1-4 carbon atoms; in some other embodiments, the alkyl group contains 1-3 carbon atoms; and in some other embodiments, the alkyl group contains 2-6 carbon atoms. Further examples of the alkyl group include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, - CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), 2-methylpropyl or isobutyl (i-Bu, -CH2CH(CH3)2), 1-methylpropyl or sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl (t-Bu, -C(CH3)3), n-pentyl (-CH2CH2CH2CH2CH3), 2-pentyl (-CH(CH3)CH2CH2CH3), 3-pentyl(-CH(CH2CH3)2), 2-methyl-2-butyl(-C(CH3)2CH2CH3), 3-methyl-2-butyl(-CH(CH3)CH(CH3)2), 3-methyl-1-butyl (-CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2, 3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3, 3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, etc. The term "alkane group" and its prefix "alkane" used herein both include straight and branched saturated carbon chains.
- The term "halogenated alkyl" refers to that alkyl may be substituted with one or more identical or different halogen atoms, which are F, Cl, Br, or I. Herein, the alkyl group has the meaning as described in the present disclosure, and examples thereof include, but are not limited to, totrifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, etc.
- The term "hydroxyl-substituted alkyl" refers to that alkyl may be substituted with one or more hydroxyl groups. Herein, the alkyl group has the meaning as described in the present disclosure, and examples thereof include, but are not limited to, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, etc.
- The term "amino" refers to -NH2.
- The term "alkoxy" used in the present disclosure involves alkyl, as defined in the present disclosure, connected to a main carbon chain through an oxygen atom. Such examples include, but are not limited to, methoxyl, ethoxy, propoxy, and the like.
- The term "cycloalkyl" refers to a monovalent or multivalent saturated monocyclic, bicyclic or tricyclic ring system containing 3-12 carbon atoms. The bicyclic or tricyclic ring system may include fused rings, bridged rings, and spiro rings. In an embodiment, cycloalkyl contains 3-10 carbon atoms; in another embodiment, cycloalkyl contains 3-8 carbon atoms; in another embodiment, cycloalkyl contains 3-6 carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like. The cycloalkyl group is optionally substituted with one or more substituents described in the present disclosure.
- The term "aryl" refers to a monocyclic, bicyclic and tricyclic carbon ring system containing 6-14 ring atoms, or 6-12 ring atoms, or 6-10 ring atoms, at least one ring of which is aromatic. The aryl group is usually, but not necessarily, connected to the core moiety through the aromatic ring of the aryl group. The term "aryl" can be used interchangeably with the term "aromatic ring". Examples of the aryl may include phenyl, naphthyl, and anthracyl. The aryl group is optionally substituted with one or more substituents described in the present disclosure.
- The term "heteroaromatic ring" refers to a monocyclic, bicyclic and tricyclic ring system containing 5-12 ring atoms, or 5-10 ring atoms, or 5-6 ring atoms, at least one ring of which is aromatic and at least one ring of which contains one or more heteroatoms. The heteroaromatic ring is usually, but not necessarily, connected to the core moiety through the aromatic ring of the heteroaromatic ring. The term "heteroaryl" can be used interchangeably with the term "heteroaromatic ring", "aromatic heterocyclic ring", or "heteroaromatic compound". The heteroaryl group is optionally substituted with one or more substituents described in the present disclosure. In an embodiment, the heteroaryl group, consisting of 5 to 10 atoms, contains 1, 2, 3, or 4 heteroatoms independently selected from O, S, or N.
- Examples of the heteroaryl include, but are not limited to, 2-finyl, 3-furyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (such as 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (such as 5-tetrazolyl), triazolyl (such as 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (such as 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiodiazolyl, 1,3,4-thiodiazolyl, 1,2,5-thiodiazolyl, pyrazinyl, 1,3,5-triazinyl. Examples of heteroaryl further include, but not limited to, the following bicyclic rings: benzimidazolyl, benzofuranyl, benzothienyl, indolyl (such as 2-indolyl), purinyl, quinolinyl (such as 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), isoquinolinyl (such as 1-isoquinolinyl, 3-isoquinolinyl or 4-isoquinolinyl), imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridyl, etc.
- As described in the present disclosure, a ring system with a substituent R' connected to a core ring of the ring system through one bond represents that the substituent R' can be substituted at any substitutable or any suitable position on the ring. For example, formula a represents that any substitutable position on the B' ring can be substituted with R', e.g., shown in formula b, formula c and formula d.
- In addition, it should be noted that, unless explicitly stated otherwise, the expressions used throughout the present disclosure such as "each of...and...is independently", "... and... are each independently" and "... and... are respectively independently" are interchangeable and should be understood in a broad sense. They mean that in different groups, the specific options expressed by the same symbols do not affect each other; or in the same group, the specific options expressed by the same symbols do not affect each other. For example, in Formula (I), among m1 (R4)s, the specific options of R4 can be identical or different; for instance, in Formula (I), the specific options of respective R4, R5 or R6 can be identical or different, and the substituents represented by R4, R5 and R6 may be identical or different.
- The term "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable when administered to humans and generally do not produce allergies or similar inappropriate reactions, such as gastrointestinal discomfort, dizziness, and the like. Preferably, the term "pharmaceutically acceptable" as used herein refers to those approved by a federal regulatory agency or a national government or recorded in the US Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, more particularly in humans.
- The term "carrier" refers to a diluent, adjuvant, excipient or matrix that is administered together with the compound. These pharmaceutical carriers can be sterile liquids such as water and oils, including those derived from petroleum, animals, plants, or synthetic sources, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, aqueous saline solution, aqueous dextrose, and glycerite are preferably used as carriers, especially for injectable solutions. Suitable carriers of medicaments are described in "Remington's Pharmaceutical Sciences", by E. W. Martin.
- The "hydrate" of the present disclosure refers to the compound or its salt provided by the present disclosure with chemical or non-chemical equivalent water bonded thereto by non-covalent intermolecular force, i.e., an associated complex formed when the solvent molecule is water.
- The "solvate" of the present disclosure refers to an associated complex formed by one or more solvent molecules and the compound of the present disclosure. The solvents for forming the solvate include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol.
- The "ester" in the present disclosure refers to esters that are formed by the compounds represented by Formula (I) to Formula (IV) containing hydroxyl and can be hydrolyzed in vivo. Such esters are, for example, pharmaceutically acceptable esters that are hydrolyzable in the human or animal body to produce alcohols. The in vivo hydrolyzable esters of the compounds represented by Formula (I) to Formula (IV) containing hydroxyl include, but are not limited to, phosphate group, acetyloxymethoxyl, 2,2-dimethyl acetyloxymethoxyl, alkanoyl, benzoyl, benzylacetyl, alkoxycarbonyl, dialkylcarbamoyl, and N-(dialkylaminoethyl)-N-alkylcarbamoyl, etc.
- The "nitrogen oxide" of the present disclosure means that, when the compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxide. Specific examples of N-oxides are N-oxides of tertiary amines or N-oxides of the nitrogen atom of nitrogen heterocycle. An oxidant such as hydrogen peroxide or peracid (such as peroxycarboxylic acid) can be used to process a corresponding amine to form N-oxide (see Advanced Organic Chemistry, Wiley Interscience, 4th edition, Jerry March, pages). In particular, N-oxides can be prepared by the method by L. W. Deady (Syn. Comm. 1977, 7, 509-514), in which, for example, the amine compound reacts with m-chloroperoxybenzoic acid (MCPBA) in an inert solvent such as dichloromethane.
- The term "prodrug" used in the present disclosure indicates a compound that is converted into a compound represented by formula (I) in vivo. Such conversion is affected by a prodrug hydrolysis in blood or an enzymatic conversion into a parent structure in blood or tissues. The prodrug compounds of the present disclosure may be esters. In the present disclosure, the esters serving as prodrugs include phenyl esters, aliphatic (C1-24) esters, acyloxymethyl esters, carbonate esters, carbamate esters and amino acid esters. For example, a compound in the present disclosure contains hydroxyl, which can be acylated to obtain a compound in the form of a prodrug. Other forms of the prodrug include phosphate esters, for example, the phosphate ester compounds obtained by phosphorylation of the hydroxyl group on the parent structure. For a full discussion of prodrugs, please refer to the following literatures: T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987 , J. Rautio et al., Prodrugs: Design and Clinical Applications, Nature Review Drug Discovery, 2008, 7, 255-270, and S. J. Hecker et al., Prodrugs of Phosphates and Phosphonates, Journal of Medicinal Chemistry, 2008, 51, 2328-2345. Prodrugs are not part of the invention.
- All tautomeric forms of the compounds of the present disclosure are included in the scope of the present disclosure, unless otherwise indicated.
- In addition, the structural formulas of the compounds described in the present disclosure include enriched isotopes of one or more different atoms, unless otherwise indicated. The present disclosure includes isotopically-labeled compounds, which are equivalent to the compounds represented by formula (I) to formula (II), but one or more atoms thereof are replaced by atoms with atomic mass or mass number different from the common atomic mass or mass number in nature. Examples of isotopes that can be introduced in the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2H, 3H, 13C, 11C, 14C, 15N, 18O, 17O, 31P, 32P, 35S, 18F and 36Cl. The compounds of the present disclosure containing the above isotopes and/or other isotopes of other atoms, and pharmaceutically acceptable salts of the compounds or the prodrugs all fall within the scope of the present disclosure. The isotopically-labeled compounds of formula (I) to formula (II) of the present disclosure and their prodrugs can generally be prepared in this way: when performing the following procedures and/or the processes disclosed in the examples and preparation examples, the non-isotopically labeled reagents are replaced by the isotopically-labeled reagents that are easily available.
- "Metabolite" refers to a product obtained by metabolizing a specific compound or its salt in vivo. The metabolite of one compound can be identified by techniques well known in the art, and its activity can be characterized by assays as described in the present disclosure. Such a product may be obtained through oxidation, reduction, hydrolysis, amidation, deamidation, esterification, degreasing, or enzyme cleavage of the administrated compound, or the like. Accordingly, the present disclosure includes the metabolites of the compound, including metabolites produced by fully contacting the compound of the present disclosure with a mammal for a period of time. Metabolites are not part of the invention.
- Various pharmaceutically acceptable salt forms of the compounds of the present disclosure are useful. The term "pharmaceutically acceptable salts" refers to the salt forms that are apparent to pharmaceutical chemists, that is, they are substantially non-toxic and can provide the desired pharmacokinetic properties, palatability, absorption, distribution, metabolism or excretion. Other factors, which are more practical in terms of properties and are also important in terms of selection, include: the cost of raw materials, ease of crystallization, yield, stability, hygroscopicity, and fluidity of the resulting crude drugs. In brief, the pharmaceutical composition can be prepared from an active component and a pharmaceutically acceptable carrier.
- As used herein, a "pharmaceutically acceptable salt" refers to an organic or inorganic salt of the compound of the present disclosure. The pharmaceutically acceptable salts are well known in the art, as described in the literature: S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19, 1977. Salts formed by pharmaceutically acceptable non-toxic acids include, but are not limited to, inorganic acid salts formed by reacting with amino groups, including hydrochloride, hydrobromide, phosphate, sulfate, perchlorate, nitrate, etc.; and organic acid salts such as acetate, propionate, glycollate, oxalate, maleate, malonate, succinate, fumarate, tartrate, citrate, benzoate, mandelate, methanesulfonate, ethanesulfonate, tosylate, sulfosalicylate, etc., or the salts obtained through other methods such as ion exchange described in book literatures.
- Other pharmaceutically acceptable salts include adipate, malate, 2-hydroxypropionic acid, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentylpropionate, digluconate, dodecyl sulfate, esilate, formate, fumarate, gluceptate, glycerophosphate, gluconate, hemisulphate, enanthate, caproate, hydriodate, 2-hydroxy-ethanesulfonate, lactobionic acid salt, lactate, laurate, lauryl sulfate, malate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, stearate, thiocyanate, p-toluene sulfonate, undecanoate, valerate, etc. Salts obtained from suitable bases include salts of alkali metal, alkaline earth metal, ammonium, and N+(C1-4 alkyl)4.
- The present disclosure also contemplates quaternary ammonium salts formed by any compound with a group containing N. Water-soluble or oil-soluble or dispersed products can be obtained by quaternization. The salts of alkali metal or alkaline earth metal include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, etc. The pharmaceutically acceptable salts further include suitable and non-toxic ammoniums, quaternary ammonium salts and amine cations formed by counterions, such as halides, hydroxides, carboxylates, hydrosulfates, phosphates, nitrates, C1-8 sulfonates and aromatic sulfonates. The ammonium salts, such as but not limited to N, N'-dibenzylethylenediamine, chloroprocaine, choline, ammonia, diethanolamine and other hydroxyalkylamines, ethylenediamine, N-methyl glucosamine, procaine, N-benzylphenethylamine, 1-p-chlorobenzyl-2-pyrrolidine-1'-ylmethyl-benzimidazole, diethylamine and other alkylamines, piperazine, and tris(hydroxymethyl)aminomethane; alkaline earth metal salts, such as but not limited to barium, calcium and magnesium; transition metal salts, for example, including, but not limited to zinc.
- In this specification, the structure shall prevail if the chemical name is different from the chemical structure.
- Unless otherwise specified, the abbreviations of any amino acids and other compounds used in the present disclosure are the commonly used and recognized abbreviations, or refer to IUPAC-IUB Commission on Biochemical Nomenclature (see Biochem. 1972, 11: 942-944).
- A first aspect of the present disclosure provides a new compound having a significant regulatory activity for liver X receptors.
- A second aspect of the present disclosure provides a new compound that has significant therapeutic effects on hyperlipidemia, fatty liver, obesity, diabetes, and metabolic syndrome, and can target at tumor energy metabolism.
- A third aspect of the present disclosure provides a method for preparing the liver X receptor regulator.
- The present disclosure provides a method for preparing the 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver X receptor regulator. The method includes the following steps: dissolving tryptamine and isobutyraldehyde in dichloromethane and performing a Pictet-Spengler reaction in an acidic environment to obtain an intermediate 1a; dissolving the intermediate 1a in tetrahydrofuran for rearrangement under the presence of N-bromosuccinimide, so as to obtain an intermediate 1b; dissolving the intermediate 1b in dichloromethane, and adding triethylamine to react with di-tert-butyl decarbonate, so as to obtain an intermediate 1c; dissolving the intermediate 1c in toluene, and adding cuprous iodide, N,N-dimethylethylenediamine, and potassium carbonate to react with m-chloroiodobenzene to obtain an intermediate 1d; dissolving the intermediate 1d in 2,4-dioxane, and adding bis(dibenzylideneacetone) palladium, bis(pinacolato)diboron, and potassium acetate to react in a nitrogen atmosphere, so as to obtain an intermediate 1e; performing a Suzuki coupling reaction with the intermediate 1e and a bromo-substituted R1 fragment to obtain an intermediate 1f; removing protecting groups from the intermediate 1f under an acidic condition, and reacting with an acid anhydride and acyl chloride containing R2 to obtain the 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver X receptor regulator.
- The compound provided by the present disclosure has a significant regulatory activity for the liver X receptor and lipid-lowering activity, and thus it can be used as a lead compound for treatment of hyperlipidemia, fatty liver, obesity, diabetes, and metabolic syndrome and for targeting at tumor energy metabolism.
- Further, by using a reporter gene method on HEK293T cells, liver X receptor regulators are screened from the compounds provided by the present disclosure. The lipid-lowering activities of the compounds in hepatocytes and adipocytes are tested on HepG2 cells and 3T3-L1 cells. It was found that
compound 2a-1 has the best regulatory activity for the liver X receptor and lipid-lowering activity, and the lipid-lowering mechanism thereof has been investigated. The results indicate that this compound exerts the lipid-lowering effect by down-regulating liver X receptor downstream genes SREBP-1c, ACC, FAS, SCD-1. At the same time,compound 2a-1 also has lipid-lowering activity in a mice hyperlipidemia model induced by Triton WR-1339. - Compared with the prior art, the present disclosure has the following beneficial effects:
- The compounds provided by the present disclosure require raw materials that are easily available, can be easily prepared, and have the significant regulatory activity for liver X receptor and lipid-lowering activity. The 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver X receptor regulator exerts the lipid-lowering effect by down-regulating the liver X receptor downstream genes SRFBP-1c, ACC, FAS, and SCD-1. Accordingly, the compounds of the present disclosure have great application prospects in the preparation of drugs for prevention and treatment of hyperlipidemia, fatty liver, obesity, diabetes, metabolic syndrome, and tumors.
- The present application is further described below in conjunction with specific embodiments and drawings, which should not be understood as limitations of the present disclosure.
-
- Specific steps are described as below.
- 1. Tryptamine (20 mmol) was dissolved in 50 mL of dichloromethane, isobutyraldehyde (20 mmol, 1eq.) was added, then trifluoroacetic acid (40 mmol, 2eq.) was slowly added, and the mixture was stirred overnight for reaction. Then, the reaction solution was added with petroleum ether and filtrated to obtain a white solid, i.e., an intermediate 1a.
- 2. The intermediate 1a (18 mmol) was dissolved in tetrahydrofuran/water solution, and N-bromosuccinimide (18 mmol, 1eq.) was added at 0°C and reacted for 4 hours. The reaction solution was extracted with ethyl acetate, washed with a saturated aqueous sodium of bicarbonate, dried over anhydrous sodium sulfate. Then, the solvent was removed by rotatory drying to obtain a crude intermediate 1b.
- 3. The intermediate 1b was dissolved in 50 mL of dichloromethane, triethylamine (20 mmol, 1.1eq.) was added, and di-tert-butyl decarbonate was slowly added. After reacting for 2 hours, the reaction solution was diluted with dichloromethane, washed with a saturated aqueous solution of sodium bicarbonate, dried over anhydrous sodium sulfate. The solvent was removed by rotatory drying to obtain a crude intermediate 1c, which was then recrystallized by adding 30 mL of petroleum ether/ethyl acetate (v/v: 5/1) to obtain an intermediate 1c.
- 4. The intermediate 1c (15 mmol) was dissolved in toluene, and then potassium carbonate (15 mmol, 1eq.), m-chloroiodobenzene (15 mmol, 1eq.), N,N-dimethylethylenediamine (0.15 mmol, 0.01eq.), and cuprous iodide (0.75 mmol, 0.05 eq.) were added. After reacting at 85°C for 10 hours under nitrogen protection; the reaction solution was diluted with dichloromethane, washed with saturated ammonium chloride and sodium chloride aqueous solution, dried over anhydrous sodium sulfate. The solvent was then removed by rotatory drying to obtain a crude intermediate 1d, which was recrystallized by adding 30 mL of petroleum ether/ethyl acetate (v/v: 5/1) to obtain an intermediate 1d.
- 5. The intermediate 1d (10 mmol) was dissolved in 2,4-dioxane, and then potassium acetate (10 mmol, 1eq.), bis(pinacolato)diboron (11 mmol, 1.1eq.), bis(dibenzylideneacetone)palladium (0.5 mmol, 0.05eq.), 4,5-bisdiphenylphosphine-9,9-dimethylxanthene (0.5 mmol, 0.05eq.) were added. After reacting at 85°C for 10 hours under nitrogen protection, the reaction solution was washed with saturated ammonium chloride and sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was removed by rotatory drying to obtain a crude intermediate 1e, which was purified through silica gel column chromatography to obtain a pure product.
- 6. The intermediate 1e (8 mmol) was dissolved in 2,4-dioxane, and then sodium carbonate (9.6 mmol, 1.2eq.), a bromo-substituted Ra derivative (9.6 mmol, 1.2eq.), and [1, 1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.4 mmol, 0.05eq.) were added. After reacting at 85°C for 10 hours under nitrogen protection, the reaction solution was diluted with dichloromethane, washed with saturated ammonium chloride and sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was removed by rotatory drying to obtain a crude product, which was purified by silica gel column chromatography to obtain
compounds 2a, 3a, 4a. - 7.
Compound 2a, 3a, or 4a was dissolved in dichloromethane, and then trifluoroacetic acid (5eq.) was added to react for 1 hour. The reaction solution was dried through rotatory drying under reduced pressure, and then a next reaction step was directly performed. The crude intermediate was dissolved in dichloromethane/pyridine (v/v: 5/1), and acid anhydride or acid chloride containing Rb was added to react overnight. The reaction solution was diluted with dichloromethane, washed with saturated sodium bicarbonate and sodium chloride aqueous solution, and dried over anhydrous sodium sulfate. The solvent was removed by rotatory drying to obtain a crude product, which was purified through silica gel column chromatography to obtain the target compounds 2b to 2e, 3b to 3f, 4b to 4c. -
- Product 1a: white solid (92%). 1H NMR (400 MHz, Methanol-d 4) δ 7.48 (dd, J = 7.95, 1.04 Hz, 1H), 7.37 (dt, J = 8.21, 0.93 Hz, 1H), 7.16 (ddd, J = 8.23, 7.04, 1.18 Hz, 1H), 7.06 (ddd, J = 8.01, 7.05, 1.01 Hz, 1H), 4.67 (dd, J = 4.02, 2.06 Hz, 1H), 3.75 (ddd, J = 12.51, 5.50, 3.28 Hz, 1H), 3.45 (ddd, J = 12.70, 9.70, 5.71 Hz, 1H), 3.18 - 3.00 (m, 2H), 2.64 (pd, J = 7.10, 4.00 Hz, 1H), 1.25 (d, J = 7.06 Hz, 3H), 0.97 (d, J = 7.07 Hz, 3H). m/z (ESI-MS): 215.3 [M + H]+.
-
Product 1c: white solid (81%). 1H NMR (400 MHz, Methanol-d 4) δ 9.45 (s, 1H), 7.24 - 7.18 (m, 1H), 7.15 (td, J = 7.73, 1.16 Hz, 1H), 6.93 (td, J = 7.61, 1.05 Hz, 1H), 6.86 (d, J = 7.72 Hz, 1H), 4.00 (dt, J = 11.02, 7.85 Hz, 1H), 3.91 (d, J = 6.05 Hz, 1H), 3.43 (ddd, J = 11.13, 7.42, 5.83 Hz, 1H), 2.20 - 2.10 (m, 2H), 2.00 - 1.86 (m, 1H), 1.42 (s, 9H), 0.94 (d, J = 6.78 Hz, 3H), 0.62 (d, J = 6.68 Hz, 3H). m/z (ESI-MS): 231.2[M + H]+ - Product 1d: white solid (58%). 1H NMR (400 MHz, Chloroform-d) δ 7.37 - 7.32 (m, 2H), 7.32 - 7.28 (m, 1H), 7.23 (m, 2H), 7.14 (td, J = 7.74, 1.16 Hz, 1H), 7.00 (t, J = 7.53 Hz, 1H), 6.75 (d, J = 7.86 Hz, 1H), 3.98 (m, 2H), 3.46 (dt, J = 11.18, 6.74 Hz, 1H), 2.21 (dd, J = 8.41, 5.45 Hz, 2H), 2.00 (h, J = 6.66 Hz, 1H), 1.39 (s, 9H), 0.94 (d, J = 6.78 Hz, 3H), 0.63 (d, J = 6.68 Hz, 3H). m/z (ESI-MS): 441.3[M + H]+
- Product 1e: white solid (63%). 1H NMR (400 MHz, Chloroform-d) δ 7.76 (d, J = 7.22 Hz, 1H), 7.72 (d, J = 2.00 Hz, 1H), 7.44 (t, J = 7.56 Hz, 1H), 7.38 (d, J = 8.44 Hz, 1H), 7.30 (d, J = 7.42 Hz, 1H), 7.13 (t, J = 7.71 Hz, 1H), 6.99 (t, J = 7.50 Hz, 1H), 6.69 (d, J = 7.88 Hz, 1H), 4.08 - 3.95 (m, 2H), 3.48 (dt, J = 11.24, 6.71 Hz, 1H), 2.23 (m, 2H), 2.02 (q, J = 6.66 Hz, 1H), 1.40 (s, 9H), 1.26 (s, 12H), 0.96 (d, J = 6.81 Hz, 3H), 0.66 (d, J = 6.65 Hz, 3H).
-
Product 2a: white solid (58%). 1H NMR (400 MHz, Chloroform-d) δ 8.14 (d, J = 1.94 Hz, 1H), 7.74 (dd, J = 7.92, 1.96 Hz, 1H), 7.59 (d, J = 7.97 Hz, 1H), 7.57 - 7.47 (m, 3H), 7.34 (t, J = 6.53 Hz, 2H), 7.16 (t, J = 7.72 Hz, 1H), 7.02 (t, J = 7.53 Hz, 1H), 6.77 (d, J = 7.92 Hz, 1H), 4.90 (d, J = 6.03 Hz, 2H), 4.11 - 3.86 (m, 2H), 3.63 (t, J = 6.34 Hz, 1H), 3.48 (dt, J = 11.17, 6.69 Hz, 1H), 3.09 (s, 3H), 2.39 - 2.20 (m, 2H), 2.04 (q, J = 6.62 Hz, 1H), 1.37 (s, 10H), 0.97 (d, J = 6.78 Hz, 3H), 0.68 (d, J = 6.67 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 177.63, 155.20, 142.50, 139.39, 139.36, 138.68, 137.77, 134.10, 131.45, 130.71, 129.36, 127.49, 127.35, 127.15, 125.75, 125.43, 124.33, 124.30, 121.89, 108.43, 78.74, 66.99, 61.10, 55.24, 44.82, 43.96, 34.42, 29.76, 27.43, 20.74.17.91. ESI-HRMS [M+H]+ m/z = 591.2520, calcd for C33H38N2O6S, 591.2523. - Product 2b: white solid (70%). 1H NMR (500 MHz, Chloroform-d) δ 8.17 (d, J = 3.11 Hz, 1H), 7.78 (d, J = 6.34 Hz, 1H), 7.58 (m, 4H), 7.36 (d, J = 7.56 Hz, 2H), 7.25 - 7.20 (m, 1H), 7.08 (d, J = 6.54 Hz, 1H), 6.81 (d, J = 7.07 Hz, 1H), 4.91 (d, J = 7.16 Hz, 1H), 4.42 (t, J = 4.50 Hz, 1H), 4.23 (q, J = 9.36 Hz, 1H), 3.88 - 3.79 (m, 1H), 3.63 (t, J = 5.63 Hz, 1H), 3.13 (d, J = 3.15 Hz, 3H), 3.12 - 3.05 (m, 2H), 2.49 (dd, J = 8.73, 3.47 Hz, 1H), 2.44 (dd, J = 8.65, 4.13 Hz, 1H), 2.18 (q, J = 7.37, 6.89 Hz, 1H), 0.99 (d, J = 5.84 Hz, 3H), 0.75 (d, J = 6.63 Hz, 3H). 13C NMR (126 MHz, Chloroform-d) δ 178.00, 157.75(q), 143.80, 140.77, 140.49, 139.41, 139.13, 134.78, 132.68, 132.19, 130.51, 129.18, 128.49, 127.08, 126.71, 126.51, 125.41, 125.31, 123.19, 116.55 (q), 109.85, 68.44, 62.65, 54.50, 45.17, 45.04, 34.38, 30.35, 22.02, 18.58. ESI-HRMS [M+H]+ m/z = 587.1819, calcd for C30H29F3N2O5S, 587.1822.
- Product 2c: white solid (84%). 1H NMR (400 MHz, Chloroform-d) δ 8.15 (d, J = 1.84 Hz, 1H), 7.75 (dd, J = 7.90, 1.90 Hz, 1H), 7.56 (dd, J = 13.86, 5.20 Hz, 5H), 7.39 - 7.27 (m, 2H), 7.24 - 7.11 (m, 1H), 7.04 (t, J = 7.55 Hz, 1H), 6.78 (d, J = 7.87 Hz, 1H), 4.91 (s, 2H), 4.42 (d, J = 6.03 Hz, 1H), 4.03 (q, J = 8.81 Hz, 1H), 3.66 (td, J = 9.58, 3.28 Hz, 1H), 3.39 (d, J = 12.98 Hz, 1H), 3.12 (s, 3H), 2.45 (dt, J = 13.30, 8.69 Hz, 1H), 2.40 - 2.32 (m, 1H), 2.19 (d, J = 14.27 Hz, 1H), 2.08 (q, J = 6.63 Hz, 1H), 1.02 (s, 8H), 0.97 (d, J = 6.88 Hz, 3H), 0.72 (d, J = 6.63 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 177.50, 171.70, 142.77, 139.65, 139.37, 138.51, 137.97, 134.06, 131.58, 131.09, 131.00, 129.34, 127.66, 127.58, 127.46, 127.32, 126.64, 125.81,125.54,124.45,124.25,121.82,108.49,65.36,61.42,53.97,45.75,45.43,44.09,33.34, 30.36,29.68,29.09,21.35, 18.06. ESI-HRMS [M+H]+ m/z = 589.2734, calcd for C34H40N2O5S, 589.2731.
- Product 2d: white solid (78%). 1H NMR (500 MHz, Chloroform-d) δ 8.15 (d, J = 1.84 Hz, 1H), 7.75 (dd, J = 7.86, 1.86 Hz, 1H), 7.58 (d, J = 7.87 Hz, 1H), 7.57 - 7.49 (m, 3H), 7.35 (dd, J = 7.61, 3.15 Hz, 2H), 7.23 - 7.14 (m, 1H), 7.04 (t, J = 7.54 Hz, 1H), 6.76 (d, J = 7.86 Hz, 1H), 4.90 (s, 2H), 4.56 (d, J = 6.76 Hz, 1H), 4.23 (dt, J = 10.47, 7.49 Hz, 1H), 3.77 (dt, J = 10.44, 7.05 Hz, 1H), 3.40 (s, 1H), 3.12 (s, 3H), 2.40 (t, J = 7.20 Hz, 2H), 2.07 (h, J = 6.79 Hz, 1H), 1.26 (s, 9H), 0.90 (d, J = 6.81 Hz, 3H), 0.65 (d, J = 6.59 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 177.67,177.11,142.79,139.65,139.39,138.47,137.93,134.13,131.59,131.00, 129.40, 127.57, 127.32, 127.12, 125.86, 125.70, 124.54, 124.14, 121.74, 108.46, 67.08, 61.42, 53.33, 45.32, 44.07, 38.44, 34.42, 29.30, 27.00, 20.88, 17.68. ESI-HRMS [M+H]+ m/z = 575.2541, calcd for C33H38N2O5S, 575.2574.
- Product 2e: white solid (63%). 1H NMR (400 MHz, Chloroform-d) δ 7.67 - 7.55 (m, 5H), 7.47 (d, J = 7.79 Hz, 2H), 7.43 (d, J = 7.61 Hz, 1H), 7.40 (dd, J = 7.46, 1.73 Hz, 1H), 7.26 (d, J = 7.84 Hz, 1H), 7.12 (t, J = 7.54 Hz, 1H), 6.92 (d, J = 7.91 Hz, 1H), 4.77 (s, 2H), 4.13 (d, J = 7.06 Hz, 2H), 3.60 (dt, J = 12.04, 6.78 Hz, 1H), 2.38 (td, J = 19.24, 16.22, 9.53 Hz, 2H), 2.14 (h, J = 6.62 Hz, 1H), 1.51 (d, J = 1.52 Hz, 9H), 1.07 (dd, J = 6.92, 1.48 Hz, 3H), 0.76 (d, J = 6.64 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 178.51, 156.16, 143.79, 142.50, 140.49, 139.48, 134.89, 130.00, 128.79, 128.37, 127.48, 127.39, 126.71, 125.45, 125.24, 122.66, 109.52, 79.79, 64.99, 56.23, 46.06, 35.76, 30.80, 29.70, 28.48, 21.49, 19.00. ESI-HRMS [M+H]+ m/z = 513.2724, calcd for C32H36N2O4, 513.2748.
- Product 3a: white solid (76%). 1H NMR (400 MHz, Chloroform-d) δ 7.62 (s, 1H), 7.61 - 7.56 (m, 3H), 7.54 (d, J = 8.00 Hz, 1H), 7.41 (t, J = 6.97 Hz, 2H), 7.36 (d, J = 7.91 Hz, 1H), 7.24 (t, J = 7.80 Hz, 1H), 7.09 (t, J = 7.55 Hz, 1H), 6.87 (d, J = 7.92 Hz, 1H), 4.09 (q, J = 7.12 Hz, 2H), 3.56 (dt, J = 12.24, 6.81 Hz, 1H), 3.14 (s, 3H), 2.90 (s, 3H), 2.40 - 2.26 (m, 2H), 2.10 (q, J = 6.67 Hz, 1H), 1.47 (s, 9H), 1.04 (d, J = 6.75 Hz, 3H), 0.74 (d, J= 6.62 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 178.51, 168.16, 156.11, 143.51, 142.24, 140.67, 135.45, 135.11, 130.86, 130.24, 128.55, 128.45, 128.27, 128.14, 126.63, 126.20, 126.07, 125.35, 125.30, 122.84, 109.41, 79.62, 74.81, 68.13, 60.33, 56.23, 45.92, 38.11, 34.68, 30.77, 28.47, 21.62. ESI-HRMS [M+H]+ m/z = 588.2617, calcd for C34H38ClN3O4, 588.2624.
- Product 3b: white solid (77%). 1H NMR (500 MHz, Chloroform-d) δ 7.64 - 7.57 (m, 1H), 7.55 (d, J = 1.59 Hz, 1H), 7.51 (t, J = 6.62 Hz, 2H), 7.47 (dd, J = 7.87, 1.60 Hz, 1H), 7.39 (td, J = 7.72, 2.71 Hz, 1H), 7.34 (dd, J = 7.02, 2.26 Hz, 2H), 7.30 (d, J = 7.90 Hz, 1H), 7.22 - 7.15 (m, 1H), 7.04 (t, J = 7.53 Hz, 1H), 4.57 (d, J = 6.78 Hz, 1H), 4.23 (dt, J = 10.47, 7.41 Hz, 1H), 3.77 (dt, J = 10.45, 6.99 Hz, 1H), 3.09 (s, 3H), 2.85 (s, 3H), 2.38 (t, J = 7.21 Hz, 2H), 2.07 (h, J = 6.80 Hz, 1H), 1.28 (s, 9H), 0.91 (d, J = 6.80 Hz, 3H), 0.64 (d, J = 6.60 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 177.57, 177.00, 167.22, 142.81, 141.25, 139.76, 134.38, 134.04, 129.27, 127.53, 127.51, 127.23, 127.21, 127.19, 125.76, 125.50, 125.11, 124.49, 124.13, 121.66, 108.43, 67.10, 53.33, 45.32, 38.44, 37.14, 34.45, 33.69, 29.30, 27.01, 20.82, 17.68. ESI-HRMS [M+H]+ m/z = 572.2659, calcd for C34H38ClN3O3, 572.2674.
- Product 3c: white solid (49%). 1H NMR (400 MHz, Chloroform-d) δ 7.64 (m, 3H), 7.58 - 7.53 (m, 1H), 7.45 (s, 1H), 7.40 (d, J = 2.49 Hz, 1H), 7.38 (t, J = 3.51 Hz, 1H), 7.29 (d, J = 2.83 Hz, 1H), 7.28 - 7.23 (m, 1H), 7.12 (d, J = 7.39 Hz, 1H), 6.91 (d, J = 8.02 Hz, 1H), 4.80 (d, J = 7.01 Hz, 1H), 4.33 (q, J = 8.46 Hz, 1H), 3.41-3.37 (m, 1H), 3.75 (td, J = 9.55, 3.82 Hz, 1H), 3.17 (s, 3H), 2.93 (s, 3H), 2.56 - 2.47 (m, 1H), 2.39 - 2.27 (m, 1H), 2.05 (brs, 3H), 1.58 (s, 6H), 0.83 (d, J = 6.66 Hz, 3H), 0.60 (d, J = 6.52 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 179.80, 176.78, 167.20, 142.65, 141.58, 139.71, 134.45, 133.95, 131.22, 129.87, 129.23, 127.77, 127.26, 127.17, 126.61, 125.70, 125.06, 124.33, 124.03, 122.08, 108.53, 73.91, 68.21, 55.48, 54.79, 53.15, 47.12, 44.25, 40.02, 37.12, 33.69, 28.26. ESI-HRMS [M+H]+ m/z = 604.2557, calcd for C34H39ClN4O2S,604.2555.
- Product 3d: white solid (43%). 1H NMR (400 MHz, Chloroform-d) δ 7.68 - 7.61 (m, 3H), 7.59 (d, J = 2.13 Hz, 1H), 7.56 (dd, J = 7.86, 1.63 Hz, 1H), 7.44 (t, J = 7.62 Hz, 2H), 7.40 (d, J = 7.92 Hz, 1H), 7.32 (t, J = 7.75 Hz, 1H), 7.16 (t, J = 7.51 Hz, 1H), 6.96 (d, J = 7.92 Hz, 1H), 4.45 (dd, J = 11.03, 8.60 Hz, 1H), 4.10 (d, J = 8.34 Hz, 1H), 3.36 (td, J = 11.63, 5.60 Hz, 1H), 3.18 (s, 3H), 2.94 (s, 3H), 2.47 (td, J = 11.99, 8.65 Hz, 1H), 2.03 - 1.93 (m, 2H), 1.97 (d, J = 7.21 Hz, 1H), 1.92 (s, 6H), 1.09 (d, J = 6.70 Hz, 3H), 0.60 (d, J = 6.76 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 176.48, 168.18, 142.56, 142.21, 140.89, 135.56, 135.13, 130.94, 130.42, 130.37, 128.40, 128.32, 128.20, 126.90, 126.09, 125.97, 125.14, 125.06, 122.97, 109.84, 84.38, 75.11, 56.94, 40.96, 40.42, 38.14, 34.72, 31.56, 28.36, 27.67, 22.09, 19.02. ESI-HRMS [M+H]+ m/z = 594.2178, calcd for C32H36ClN3O4S, 594.2188.
- Product 3e: white solid (75%). 1H NMR (400 MHz, Chloroform-d) δ 7.62 (d, J = 1.72 Hz, 1H), 7.58 (dq, J = 4.12, 2.68, 1.96 Hz, 3H), 7.54 (dd, J = 7.92, 1.74 Hz, 1H), 7.41 (ddd, J = 7.02, 3.24, 1.68 Hz, 2H), 7.37 (d, J = 7.92 Hz, 1H), 7.29 - 7.22 (m, 1H), 7.11 (td, J= 7.58, 1.09 Hz, 1H), 6.87 (d, J = 7.86 Hz, 1H), 4.48 (d, J = 6.05 Hz, 1H), 4.10 (dt, J = 10.05, 8.30 Hz, 1H), 3.72 (td, J = 9.49, 3.36 Hz, 1H), 3.16 (s, 3H), 2.91 (s, 3H), 2.51 (dt, J = 13.15, 8.72 Hz, 1H), 2.41-2.36 (m, 1H), 2.37 (d, J = 14.32 Hz, 1H), 2.28 (d, J = 14.28 Hz, 1H), 2.15 (h, J = 6.88 Hz, 1H), 1.11 (s, 9H), 1.04 (d, J = 6.83 Hz, 3H), 0.78 (d, J = 6.65 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 177.42,171.59,167.22,142.78,141.23,139.73,134.39,133.93,129.85,129.21, 127.60, 127.23, 127.19, 126.69, 125.70, 125.31, 125.09, 124.40, 124.23, 121.74, 108.46, 65.33, 53.94, 45.72, 45.39, 37.13, 33.69, 33.32, 30.34, 29.68, 29.08, 21.31, 18.05. ESI-HRMS [M+H]+ m/z = 586.2834, calcd for C35H40ClN3O3, 586.2831.
- Product 3f: white solid (61%). 1H NMR (400 MHz, Chloroform-d) δ 7.58 - 7.49 (m, 4H), 7.48 (s, 1H), 7.44 (dd, J = 8.00, 1.78 Hz, 1H), 7.33 (td, J = 6.08, 3.36 Hz, 2H), 7.184 (t, J = 6.85 Hz 1H), 7.03 (t, J = 6.76 Hz 1H), 6.81 (d, J = 7.92 Hz, 1H), 4.75 (s, 2H), 4.03 (d, J = 6.58 Hz, 2H), 3.50 (dt, J = 11.50, 7.22 Hz, 1H), 2.37 - 2.14 (m, 1H), 2.05 (dt, J = 13.26, 6.87 Hz, 2H), 1.41 (d, J = 3.89 Hz, 9H), 0.98 (d, J = 6.77 Hz, 3H), 0.68 (d, J = 6.63 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 177.50, 155.15, 142.61, 140.09, 139.85, 136.58, 133.96, 132.09, 129.13, 128.04, 127.61, 127.39, 126.86, 125.62, 124.94, 124.75, 124.26, 124.20, 121.73, 108.43, 78.72, 61.51, 56.40, 49.84, 44.96, 34.60, 29.78, 27.45, 20.55, 17.95. ESI-HRMS [M+H]+ m/z = 545.2554, calcd for C33H37ClN2O3, 545.2565.
- Product 4a: white solid (75%). 1H NMR (400 MHz, Chloroform-d) δ 7.73 (td, J = 8.43, 7.83, 3.14 Hz, 3H), 7.62 (t, J = 7.79 Hz, 1H), 7.57 (s, 1H), 7.45 (d, J = 7.58 Hz, 1H), 7.43 - 7.40 (m, 1H), 7.38 (dd, J = 7.85, 1.77 Hz, 1H), 7.32 - 7.19 (m, 1H), 7.18 - 7.05 (m, 2H), 6.95 (d, J = 7.91 Hz, 1H), 6.54 (d, J = 3.05 Hz, 1H), 4.17 (d, J = 5.78 Hz, 2H), 3.87 (s, 3H), 3.62 (ddd, J = 11.26, 7.78, 5.71 Hz, 1H), 2.39 (overlapped, 2H), 2.17 (q, J = 6.66 Hz, 1H), 1.53 (s, 9H), 1.10 (d,J= 6.76 Hz, 3H), 0.80 (d, J = 6.67 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 177.49, 155.15,143.23,142.95,136.15,133.72,132.93,128.84,128.77,127.73,127.34,127.14,126.11, 124.51, 124.16, 123.70, 121.53, 120.12, 118.15, 108.59, 106.89, 99.83, 78.63, 67.16, 55.44, 45.04, 34.71, 31.91, 29.78, 27.47, 20.49, 17.98. ESI-HRMS [M+H]+ m/z = 536.2912, calcd for C34H37N3O4, 536.2908.
- Product 4b: white solid (82%). 1H NMR (500 MHz, Chloroform-d) δ 7.63 (d, J = 9.08 Hz, 2H), 7.59 (d, J = 6.69 Hz, 1H), 7.50 (t, J = 7.82 Hz, 1H), 7.46 (s, 1H), 7.34 (d, J = 7.52 Hz, 1H), 7.30 (dd, J = 8.31, 1.43 Hz, 1H), 7.25 (d, J = 7.57 Hz, 1H), 7.16 (d, J = 7.73 Hz, 1H), 7.06 - 6.96 (m, 2H), 6.81 (d, J = 7.89 Hz, 1H), 6.43 (d, J = 3.04 Hz, 1H), 4.59 (d, J = 6.79 Hz, 1H), 4.25 (dt, J = 10.33, 7.36 Hz, 1H), 3.78 (overlapped, 4H), 2.44 - 2.35 (m, 2H), 2.08 (h, J = 6.83 Hz, 1H), 1.29 (s, 9H), 0.91 (d, J = 6.83 Hz, 3H), 0.66 (d, J = 6.61 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 177.56, 161.42, 143.26, 136.14, 133.66, 132.95, 128.90, 128.75, 127.43, 127.33, 127.10, 126.25, 124.63, 124.00, 123.98, 121.39, 120.10, 118.17, 108.63, 106.97, 99.81, 67.17, 53.37, 45.41, 38.46, 34.60, 31.97, 29.33, 27.03, 20.76, 17.71. ESI-HRMS [M+H]+ m/z = 520.2945, calcd for C34H37N3O2, 520.2959.
- Product 4c: white solid (80%). 1H NMR (500 MHz, Chloroform-d) δ 7.66 - 7.60 (m, 2H), 7.59 (dd, J = 4.48, 2.71 Hz, 1H), 7.50 (t, J = 7.84 Hz, 1H), 7.47 (s, 1H), 7.33 (d, J = 7.56 Hz, 1H), 7.30 (dd, J = 8.26, 1.41 Hz, 1H), 7.25 (d, J = 8.13 Hz, 1H), 7.17 (d, J = 7.77 Hz, 1H), 7.06 - 6.92 (m, 2H), 6.82 (d, J = 7.90 Hz, 1H), 6.43 (d, J = 3.02 Hz, 1H), 4.44 (d, J = 6.06 Hz, 1H), 3.78 (s, 3H), 3.67 (dd, J = 9.61, 3.51 Hz, 1H), 3.63 (brs, 1H), 2.44 (dt, J = 13.25, 8.66 Hz, 1H), 2.38-2. 30 (m, 2H), 2.29 (d, J = 14.34 Hz, 1H), 2.23 (d, J = 14.31 Hz, 1H), 2.10 (h, J = 6.75 Hz, 1H), 1.05 (s, 9H), 0.98 (d, J = 6.79 Hz, 3H), 0.73 (d, J = 6.67 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 177.42,170.14,143.23,136.14,133.57,132.91,128.85,128.76,127.52,127.11, 126.79, 126.20, 124.54, 124.11, 123.85, 121.47, 120.10, 118.16, 108.65, 106.96, 99.80, 65.36, 53.96, 45.74, 45.44, 33.45, 31.97, 30.34, 29.70, 21.28, 20.03, 18.07. ESI-HRMS [M+H]+ m/z = 534.3109, calcd for C35H39N3O2, 534.3115.
-
- (1) Cell culture: human embryonic kidney cells (HEK293T cells) were cultured in DMEM (high glucose) medium containing 10% fetal bovine serum and 1% penicillin-streptomycin under conditions of 37 °C and 5% CO2.
- (2) Transfection: HEK293T cells were seeded in a 96-well plate with a cell density of 2×104 cells/well. After 24 hours, the cells were transfected according to instructions of Lipofectamine™ 3000 reagent. The specific steps of transfection were as follows:
- ① adding 15µL of L3000 reagent to 500µL of DMEM (high sugar) medium, and vortex oscillating for 2 seconds;
- ② mixing 6.5µg of pGL3/(DR-4)-c-fos-FF-luc plasmid, 0.13µg of pCMV/Renilla-luc plasmid, 1.3µg of pSG5/hLXRα (or pSG5/hLXRβ plasmid), 1.3µg of pSG5/hRXRα plasmid, and 19µL of P3000 reagent in 500 µL of DMEM (high sugar) medium;
- ③ adding the plasmid mixture to a liposome mixture and standing by at room temperature for 20 minutes; and
- ④ adding 10µL of liposome-DNA solution to each well of the 96-well plate, and gently shaking the 96-well plate to mix well.
- (3) Drug intervention: after 5 hours of transfection, the compounds to be tested were added, and the plate was placed in an incubator to continue culturing for 20 hours.
- (4) Detection: dual-luciferase reporter gene system was used for detection. The specific steps of detection were as follows:
- ① aspirating the original medium in the 96-well plate, adding cell lysate to the 96-well plate at 20µL/well, and quickly shaking the plate at room temperature for 20 minutes;
- ② adding samples to a 384-well plate at 2µL/well;
- ③ adding firefly luciferase substrate to each well at 10µL/well, and measuring chemiluminescence after 7 seconds; and
- ④ adding Renilla luciferase substrate to the same sample well at 10µL/well, and measuring chemiluminescence after 7 seconds.
- Result processing: the results were analyzed using Renilla luciferase activity to correct the firefly luciferase activity. The liver X receptor inverse agonist activity of the compounds is shown in Table 1. By analyzing Table 1, it can be found that
compounds compound 2a-1 has the best inverse agonist activity, and thus it was used for the study of lipid-lowering activity and mechanism. In addition, the liver X receptor agonist activities of the compounds are shown in Table 2. From Table 2, it can be seen that compounds 3a, 3b, and 3c can activate liver X receptors.[Table 1] Liver X receptor inverse agonist activity of the compounds Compound LXRα LXRβ IC50 (µM)a % Inverse agonist effectb IC50 (µM)a % Inverse agonist effectb SR9238 0.16 93 0.10 78 2a 3.23 77 0.39 83 2a-1 2.25 81 0.36 85 2a-2 9.06 56 1.04 75 2b 8.16 50 3.44 59 2c 8.57 46 1.79 77 2e NA NA 8.64 59 2d 7.54 55 2.40 78 3d 3.56 66 4.57 56 3c NA NA NA NA 3f NA NA 6.97 51 4a NA NA NA NA 4b NA NA NA NA 4c NA NA 10.08 64 [Table 2] Liver X receptor agonist activity of the compounds. Compound LXRα LXRβ EC50(µM)a % Agonist effectb EC50(µM)a % Agonist effectb GW3965 0.36 100 0.21 100 3a 6.92 53 NA NA 3b 3.67 76 3.04 50 3c 7.83 89 4.90 60 Notes: In Table 1 and Table 2, NA means no activity was exhibited in the test range, and NT means not tested. -
- (1) Cell culture: human liver cancer cells (HepG2 cells) and mouse pre-adipocytes (3T3L1 cells) were cultured in DMEM (high glucose) medium containing 10% fetal bovine serum and 1 % penicillin-streptomycin under conditions of 37 °C and 5% CO2.
- (2) HepG2 cells were seeded in a 12-well plate, cultured with DMEM (low sugar) medium and starved for 12 hours. When the cells grow to a density of 70%, the medium was changed to DMEM (high sugar) medium and the compound was added to act for 24 hours.
- (3) The steps of differentiation preadipocytes 3T3-L1 were as follows:
Cells were seeded in a 48-well plate, cultured in complete medium until the cells were completely in contact (day 0), and the medium was changed to a differentiation medium I (complete medium supplemented with 2µg/mL of insulin, 100ng/mL of dexamethasone, 0.5mM of 3-isobutyl-1-methylxanthine, and 10ng/mL of biotin) to culture for 3 days. The blank control group was still continued being cultured with the complete medium. Onday 3, the medium was changed to a differentiation medium II (complete medium supplemented with 2µg/mL of insulin) and culturing was continued for 3 days. On day 6, the cells were harvested for subsequent analysis. - (4) Triglyceride test: the treated cells were harvested, washed twice with icy PBS (0.2 M NaCl, 10 mM Na2HPO4, 3 mM KCl, 2 mM KH2PO4, pH 7.4), breaking the cells with ultrasonic waves, and detecting absorbance at 510 nm using the triglyceride detection kit (Nanjing Jiancheng Bioengineering Institute).
- The detection results of the triglyceride content (
FIG. 1 ) indicate that, at a concentration of 10µM, thecompound 2a-1 can significantly reduce the triglyceride accumulation in HepG2 cells induced by high glucose. In addition, thecompound 2a-1 lowers the triglyceride level in 3T3-L1 cells in a concentration-dependent manner, with an IC50 of 0.27 ± 0.03 µM. The above results substantiate that thecompound 2a-1 has significant lipid-lowering activity in HepG2 cells and 3T3-L1 cells. - HepG2 cells were seeded in a 6-well plate with a cell density of 8×105 cells/well and incubated for 24 hours. The compounds to be tested were added and acted for 24 hours, and then the cells were harvested. The 3T3-L1 cells were harvested on day 6 of differentiation. The cells were washed twice with PBS, total RNA was extracted with RNAiso plus reagent, 1µg of total RNA was reverse transcribed into cDNA using ReverTra Ace qPCR RT Master Mix, and PCR amplification was performed using SYBR Green Realtime PCR Master Mix.
- As shown in
FIG. 2 , in 3T3-L1 cells, thecompound 2a-1 reduced the mRNA content of SREBP-1c, ACC, FAS and SCD-1 in a concentration-dependent manner. In HepG2 cells, thecompound 2a-1 significantly reduced the mRNA content of these four genes. The above results prove that thecompound 2a-1 can inhibit the expressions of SREBP-1c, ACC, FAS, and SCD-1 in 3T3-L1 cells and HepG2 cells, thereby inhibiting fat synthesis. - 6-week-old SPF female C57BL/6J mice were purchased from the Experimental Animal Center of Sun Yat-sen University. The mice were randomly divided into 4 groups each including 6 mice, i.e., a normal control group, model a group, a fenofibrate group (100 mg/kg), and a B1 group (100 mg/kg), and intragastric administration was performed for 8 days. 24 hours before the last administration, the normal control group was intramuscularly injected with saline, and the remaining groups were injected with Triton WR-1339 (1500 mg/kg). One hour after the last administration, the eyeballs were removed to collect blood, the mice were executed by cervical dislocation, and the livers were collected. The plasma was allowed to stand for 1 hour, and the supernatant was collected by centrifugation at 4 °C and 3000 rpm. 100 mg of liver was weighed, added with methanol in 3 times the volume of the weighed liver, and homogenized thoroughly. Chloroform was then added in 6 times the volume and vortex oscillated. After centrifuging at 3000 rpm for 10 minutes, the lower chloroform layer was collected, and evaporated naturally overnight in a fume hood. 150µL of 1% Triton ethanol was added and heated at 65°C to be fully dissolved. Finally, triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in serum and liver samples were detected.
- As illustrated in
FIG. 3 , the positive drug, fenofibrate andcompound 2a-1, can significantly inhibit the increases in TG level, TC level, LDL-C level, and HDL-C level that are induced by Triton WR-1339. Neither fenofibrate norcompound 2a-1 had a significant effect on HDL-C/TC, butcompound 2a-1 slightly increased HDL-C/LDL-C level. The above results indicate that thecompound 2a-1 can significantly reduce the blood lipid levels in the Triton WR-1339-induced hyperlipidemia mice. At the same time,compound 2a-1 can reduce the triglyceride content in the livers of mice. There were no significant differences in liver cholesterol levels between the groups. The above results indicate thatcompound 2a-1 can significantly reduce the accumulation of triglycerides in the livers of Triton WR-1339-induced hyperlipidemia mice. In summary,compound 2a-1 also has significant lipid-lowering activity in mice. - The above experimental results indicate that the compound of the present disclosure has the significant inverse agonist activity for the liver X receptor, and can inhibit the expressions of target genes SREBP-1c, ACC, FAS and SCD-1 of liver X receptors to have lipid-lowering effect. Therefore, the compound of the present disclosure can be used as a lead compound for the treatment of hyperlipidemia, fatty liver, obesity, diabetes, and metabolic syndrome and for targeting tumor energy metabolism.
- In the description of this specification, the description referring to the terms "an embodiment", "some embodiments", "an example", "specific examples", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present disclosure. In this specification, the schematic expression of the above terms does not necessarily refer to the same embodiment or example. Moreover, the described specific features, structures, materials, or characteristics may be combined in any one or more embodiments or examples in any suitable manner. In addition, without contradicting each other, different embodiments or examples and features of different embodiments or examples described in the specification can be combined by those skilled in the art.
- Although the embodiments of the present disclosure have been shown and described above, it should be understood that the above-mentioned embodiments are illustrative and shall not be interpreted as limiting the present disclosure, and within the scope of the present disclosure, those skilled in the art can make changes, modifications, replacements and variations to the above embodiments.
Claims (15)
- A compound, being a compound represented by Formula (I); or being a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (I):wherein X1 and X2 are independently C(R7a)2;wherein R1 is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, C1-6 halogenated alkoxyl, -C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, - NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, R7bS(=O)2-, C6-10 aryl, or heteroaryl consisting of 5-12 atoms, wherein one, two, three, four or five carbon atoms of the C6-10 aryl or heteroaryl consisting of 5-12 atoms are independently and optionally substituted with R10,wherein R10 is each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, C1-6 halogenated alkoxyl, -C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, or R7bS(=O)2-;wherein R2 is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, - C(=O)NR8aR8b, -C(=S)NR8aR8b, -NR8C(=O)R7c, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7c, or R7cS(=O)2-;wherein R3 is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, oxo, or C1-6 alkyl;wherein R4, R5, and R6 are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, or C1-6 alkyl;wherein R7a, R7b, R7c, R8, R8a, and R8b are each independently H, D, F, Cl, Br, I, -CN, - NO2, -OH, -NH2, -COOH, C1-6 alkyl, or C1-6 halogenated alkyl; andwherein m1, m2, and n1 are independently 0, 1, 2, 3, or 4.
- The compound according to claim 1, wherein R1 is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, C1-4 halogenated alkoxyl, -C(=O)R7b, -C(=O)OR7b, - OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, R7bS(=O)2-, C6-10 aryl, or heteroaryl consisting of 5-10 atoms, wherein one, two, three, four or five carbon atoms of the C6-10 aryl or heteroaryl consisting of 5-10 atoms are independently and optionally substituted with R10,
wherein R10 is each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, C1-4 halogenated alkoxyl, -C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, or R7bS(=O)2-. - The compound according to claim 1, wherein R1 is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, -C(=O)R7b, - C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, R7bS(=O)2-, C6-10 aryl, or heteroaryl consisting of 5-10 atoms, wherein one, two, three, four or five carbon atoms of the C6-10 aryl or heteroaryl consisting of 5-10 atoms are independently and optionally substituted with R10;
wherein R10 is each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxy ethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, -C(=O)R7b, -C(=O)OR7b, - OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, or R7bS(=O)2-. - The compound according to claim 1, wherein R4, R5, and R6 are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, or C1-4 alkyl; and
wherein R7a, R7b, R7c, R8, R8a, and R8b are each independently H, D, F, Cl, Br, I, -CN, - NO2, -OH, -NH2, -COOH, C1-4 alkyl, or C1-4 halogenated alkyl. - The compound according to claim 1, wherein R4, R5, and R6 are each independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, or n-butyl; and
wherein R7a, R7b, R7c, R8, R8a, and R8b are each independently H, D, F, Cl, Br, I, -CN, - NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, or 3,3,3-trifluoropropyl. - The compound according to claim 4, wherein the compound is a compound represented by Formula (II-1) or (II-2); or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (II-1) or (II-2),
- The compound according to claim 6, wherein R11, R12, R13, R14, or R15 is independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, C1-4 halogenated alkoxyl, -C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, -R8N-S(=O)2R7b, or R7bS(=O)2-.
- The compound according to claim 6, wherein R11, R12, R13, R14, or R15 is independently H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, - C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, -NR8C(=O)R7b, R8aR8bN-S(=O)2-, - R8N-S(=O)2R7b, or R7bS(=O)2-.
- The compound according to claim 6, wherein the compound is a compound represented by Formula (II-1-A), (II-1-B), or (II-I-C); or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (II-1-A), (II-1-B), or (II-1-C),wherein R2a is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, or R7cS(=O)2-; R12a is R7bS(=O)2-; R13a is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, or C1-6 halogenated alkoxy;wherein R2b is R7cS(=O)2-; and R12b and R13b are each independently H, D, F, Cl, Br, I, - CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, C1-6 halogenated alkoxyl,-C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, or -NR8C(=O)R7b; andwherein R2c is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, - C(=S)NR8aR8b, -C(=O)NR8aR8b, or -NR8C(=O)R7c; R12c is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C1-6 halogenated alkyl, C1-6 hydroxyl-substituted alkyl, C1-6 alkoxyl, or C1-6 halogenated alkoxy; and R13c is - C(=O)NR8aR8b, or -NR8C(=O)R7b.
- The compound according to claim 9, wherein R2a is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, or R7cS(=O)2-; R12a is R7bS(=O)2-; and R13a is H, D, F, Cl, Br, I, - CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, or C1-4 halogenated alkoxy;wherein R2b is R7cS(=O)2-; and R12b and R13b are each independently H, D, F, Cl, Br, I, - CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, C1-4 halogenated alkoxyl, - C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, or -NR8C(=O)R7b; andwherein R2c is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, - C(=S)NR8aR8b, -C(=O)NR8aR8b, or -NR8C(=O)R7c; R12c is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 cycloalkyl, C1-4 halogenated alkyl, C1-4 hydroxyl-substituted alkyl, C1-4 alkoxyl, or C1-4 halogenated alkoxy; and R13c is - C(=O)NR8aR8b, or -NR8C(=O)R7b.
- The compound according to claim 9, wherein R2a is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, or R7cS(=O)2-; R12a is R7bS(=O)2-; and R13a is H, D, F, Cl, Br, I, - CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, or 3,3,3-trihydroxypropyl;wherein R2b is R7cS(=O)2-; and R12b and R13b are each independently H, D, F, Cl, Br, I, - CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, 3,3,3-trihydroxypropyl, - C(=O)R7b, -C(=O)OR7b, -OC(=O)R7b, -C(=O)NR8aR8b, or -NR8C(=O)R7b; andwherein R2c is -C(=O)R7c, -C(=O)(C(R7a)2)n1R7c, -C(=O)OR7c, -OC(=O)R7c, - C(=S)NR8aR8b, -C(=O)NR8aR8b, or -NR8C(=O)R7c; R12c is H, D, F, Cl, Br, I, -CN, -NO2, -OH, -NH2, -COOH, methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-butyl, trifluoromethyl, 1-chloroethyl, difluoromethyl, 2-fluoroethyl, 3,3,3-trifluoropropyl, hydroxymethyl, 1-hydroxyethyl, dihydroxymethyl, 2-hydroxyethyl, or 3,3,3-trihydroxypropyl; and R13c is - C(=O)NR8aR8b, or -NR8C(=O)R7b.
- The compound according to claim 9, wherein the compound is a compound represented by Formula (II-1-A-a), (II-1-A-b), (II-1-B-a), (II-1-B-b), (II-1-C-a), or (II-1-C-b); or the compound is a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, solvate, or pharmaceutically acceptable salt of the compound represented by Formula (II-1-A-a), (II-1-A-b), (II-1-B-a), (II-1-B-b), (II-1-C-a), or (II-1-C-b),
- A pharmaceutical composition, comprising:the compound according to any one of claims 1 to 13; andan additional therapeutic agent,wherein the additional therapeutic agent is optionally a medicament for treatment of hyperlipidemia, fatty liver, obesity, diabetes, metabolic syndrome, or a combination thereof, and preferably, the additional therapeutic agent is atorvastatin, gemfibrozil, acpimox, Eicosapentaenoic acid, metformin, glimepiride, repaglinide, empagliflozin, or any combination thereof; andwherein the additional therapeutic agent is optionally a medicament for treatment of glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, osteoporosis, or a combination thereof; and preferably, the additional therapeutic agent is temozolomide, fotemustine, statin, fibrate, trihexyphenidyl, aspirin, non-steroidal anti-inflammatory medicament, or any combination thereof, preferably, wherein the statin is lovastatin or simvastatin; the fibrate is clofibrate, lifibrate, or bezafibrate; and the non-steroidal anti-inflammatory medicament is diclofenac, nabumetone, or meloxicam.
- The compound according to any one of claims 1 to 13 or the pharmaceutical composition according to claim 14 for use in manufacture of a medicament, whereinthe medicament is used for treatment or prevention of hyperlipidemia, fatty liver, obesity, diabetes or metabolic syndrome, or for targeting tumor energy metabolism; orthe medicament is used for treatment or prevention of glioblastoma, atherosclerosis, dyslipidemia, metabolic syndrome, Parkinson's disease, Alzheimer's disease, multiple sclerosis, atopic dermatitis, rheumatoid arthritis, osteoporosis or a combination thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910652093.9A CN110305141B (en) | 2019-07-18 | 2019-07-18 | Spiro (3, 3' -isopropyl pyrrole alkoxylated indole) liver X receptor regulator and preparation method and application thereof |
PCT/CN2020/083073 WO2021008173A1 (en) | 2019-07-18 | 2020-04-02 | Spiro (3,3'-isopropyl pyrrolidine oxindole) liver x receptor regulator, preparation method therefor, and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3992195A1 EP3992195A1 (en) | 2022-05-04 |
EP3992195A4 EP3992195A4 (en) | 2022-07-27 |
EP3992195B1 true EP3992195B1 (en) | 2023-08-16 |
Family
ID=68081549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20841629.7A Active EP3992195B1 (en) | 2019-07-18 | 2020-04-02 | Spiro (3,3'-isopropyl pyrrolidine oxindole) liver x receptor regulator, preparation method therefor, and use thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220135579A1 (en) |
EP (1) | EP3992195B1 (en) |
JP (1) | JP7432704B2 (en) |
CN (1) | CN110305141B (en) |
WO (1) | WO2021008173A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110305141B (en) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | Spiro (3, 3' -isopropyl pyrrole alkoxylated indole) liver X receptor regulator and preparation method and application thereof |
CN110330498B (en) * | 2019-07-18 | 2022-03-08 | 麻王医药(深圳)有限公司 | Spiro (3, 3' -phenylpyrrole alkoxylated indole) liver X receptor regulator and preparation method and application thereof |
CN112876488B (en) * | 2021-02-18 | 2021-12-21 | 苏州大学 | Spiro indoline derivative and preparation method and application thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2564563C (en) * | 2004-05-03 | 2011-07-05 | F. Hoffmann-La Roche Ag | Indolyl derivatives as liver-x-receptor modulators |
TWI350168B (en) * | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
JP5420408B2 (en) * | 2006-08-25 | 2014-02-19 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
MX2011012559A (en) * | 2009-05-28 | 2012-06-08 | Exelixis Patent Co Llc | Lxr modulators. |
WO2014085453A2 (en) * | 2012-11-29 | 2014-06-05 | The Scripps Research Institute | Small molecule lxr inverse agonists |
DK3041835T3 (en) * | 2013-09-04 | 2020-07-13 | Ellora Therapeutics Inc | Modules of hepatic X receptors (LXR) |
WO2016100619A2 (en) * | 2014-12-17 | 2016-06-23 | Rgenix, Inc. | Treatment and diagnosis of cancer |
CN106008532B (en) * | 2016-07-20 | 2019-06-07 | 贵州大学 | Alcoxyl yl pyrimidines splice 3- pyrroles's loop coil oxoindole derivative and preparation method and application |
CN110305141B (en) * | 2019-07-18 | 2022-01-11 | 深圳市三启药物开发有限公司 | Spiro (3, 3' -isopropyl pyrrole alkoxylated indole) liver X receptor regulator and preparation method and application thereof |
CN110330498B (en) * | 2019-07-18 | 2022-03-08 | 麻王医药(深圳)有限公司 | Spiro (3, 3' -phenylpyrrole alkoxylated indole) liver X receptor regulator and preparation method and application thereof |
-
2019
- 2019-07-18 CN CN201910652093.9A patent/CN110305141B/en active Active
-
2020
- 2020-04-02 JP JP2022503560A patent/JP7432704B2/en active Active
- 2020-04-02 WO PCT/CN2020/083073 patent/WO2021008173A1/en unknown
- 2020-04-02 EP EP20841629.7A patent/EP3992195B1/en active Active
-
2022
- 2022-01-17 US US17/577,018 patent/US20220135579A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3992195A1 (en) | 2022-05-04 |
JP7432704B2 (en) | 2024-02-16 |
US20220135579A1 (en) | 2022-05-05 |
CN110305141B (en) | 2022-01-11 |
CN110305141A (en) | 2019-10-08 |
WO2021008173A1 (en) | 2021-01-21 |
JP2022541298A (en) | 2022-09-22 |
EP3992195A4 (en) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3992195B1 (en) | Spiro (3,3'-isopropyl pyrrolidine oxindole) liver x receptor regulator, preparation method therefor, and use thereof | |
JP6761821B2 (en) | Etinyl derivative as a metabolic glutamate receptor modulator | |
KR20230129627A (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
TW201904974A (en) | Heteroarylpyrimidinone derivative, preparation method thereof and use thereof in medicine | |
JP2021046428A (en) | Pyridopyrimidinones and their use as nmda receptor modulators | |
US20220153688A1 (en) | Hydrazone amide derivatives and use thereof in preparation of anti-osteoporosis drugs | |
JP6138150B2 (en) | [1,2,4] Triazolopyridine and its use as phosphodiesterase inhibitor | |
JP2021519316A (en) | Compounds as regulators of TLR2 signaling | |
KR20120101551A (en) | Bicyclic thiazoles as allosteric modulators of mglur5 receptors | |
CN111499591A (en) | ROR gamma modulators | |
WO2021150645A1 (en) | Novel cell metabolism modulating compounds and uses thereof | |
WO2021008014A1 (en) | Spiro (3,3'-phenylpyrrolidine oxyindole) liver x receptor modulator and preparation method therefor and application thereof | |
CN115803085A (en) | Novel cell metabolism regulating compounds and uses | |
CN116874465B (en) | Pyrimidine compound and application thereof | |
WO2017190038A1 (en) | Analogs of yohimbine and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220127 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220628 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 19/10 20060101ALI20220622BHEP Ipc: A61P 19/02 20060101ALI20220622BHEP Ipc: A61P 17/00 20060101ALI20220622BHEP Ipc: A61P 25/28 20060101ALI20220622BHEP Ipc: A61P 25/16 20060101ALI20220622BHEP Ipc: A61P 9/10 20060101ALI20220622BHEP Ipc: A61P 35/00 20060101ALI20220622BHEP Ipc: A61P 3/00 20060101ALI20220622BHEP Ipc: A61P 3/10 20060101ALI20220622BHEP Ipc: A61P 3/04 20060101ALI20220622BHEP Ipc: A61P 1/16 20060101ALI20220622BHEP Ipc: A61P 3/06 20060101ALI20220622BHEP Ipc: A61K 31/407 20060101ALI20220622BHEP Ipc: C07D 487/10 20060101AFI20220622BHEP |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230228 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602020015981 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20230816 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1599975 Country of ref document: AT Kind code of ref document: T Effective date: 20230816 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231117 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231216 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231218 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231116 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231216 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231117 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230816 |